Urgent Whole-Profile Seriousness Triage

whole-profile · triage · lp(a) · occult-blood · thrombocytosis · bloating · health-anxiety · red-flags

Whole-Profile Seriousness Triage

Summary

This page is the forest-before-trees router. It does not replace the detailed topic pages; it ranks what deserves attention first.

The current profile is not one single crisis. It is a few high-consequence branches plus several high-noise symptom branches. Old RPPH papers found in June 2026 add a durable cardiovascular anchor: 2024-01-22 right common-femoral plaque / mild PAD, 24-31% stenosis, probably incidental to the hip symptom but not irrelevant to prevention. The completed clean-month blood/stool pattern improved, strengthening alcohol/smoking avoidance as a high-value stabilizer. The useful operating rule is: red flags override the plan; otherwise, use objective labs/stool/logs/BP/imaging to reduce uncertainty before adding procedures.

One-page hierarchy

What can kill or permanently harm

1. Acute coronary syndrome / unstable cardiac symptoms. The early-April severe epigastric/upper-abdominal pain pattern with sweating, dizziness, and arm/hand symptoms must stay in cardiac rule-out logic if it recurs.
2. Major GI bleeding. Visible red/maroon/black stool, clots, presyncope, tachycardia, or rapid weakness overrides normal monitoring.
3. Atherosclerotic / aortic-valve disease from very high Lp(a). Mild right common-femoral plaque was already documented in 2024; coronary and valve burden remain unstaged. This is less dramatic day-to-day but probably the largest lifetime-risk anchor.
4. Unexplained persistent thrombocytosis/leukocytosis. Reactive causes are common, but persistence after cleanup needs hematology-style branching rather than reassurance.

What is likely symptom burden rather than the main danger signal

• Post-meal bloating, distension, urgency, and gas fit the SIBO/MMC/SUDD/food-load branch better than the bleed branch.
• New weak migrating spot pains can belong to gas trapping, visceral hypersensitivity, abdominal wall strain, constipation, SUDD/IBS overlap, or benign transient pains.
• Historical right hip discomfort workup in 2024 found no fracture/dislocation, minimal bilateral hip osteoarthritis worse on the right, and one report suggesting possible gluteal calcific tendinitis. That is a musculoskeletal context note, not an abdominal/GI red flag.
• These symptoms deserve tracking because they affect life quality and can guide low-risk trials. They should not be allowed to overrule objective blood/stool/cardiac signals.

What is modifiable now

• Zero smoking and zero alcohol for the current experiment.
• BP measurement using the existing home/ABPM protocol.
• ApoB/LDL risk reduction with atorvastatin and imaging-guided escalation discussion; the 2024 mild PAD finding lowers the threshold for cardiology prevention review.
• NSAID and primary-prevention aspirin avoidance while stool-blood risk is live.
• Meal spacing, final-week coffee-reduction/tea-substitution context with tea/iron timing, vegetarian iron + vitamin-C pairing, stool photos, and circumference tracking.
• Repeat labs/stool at the planned decision point rather than adding scattered one-off tests.

What can wait

• Broad microbiome testing, supplement shopping, and exotic inflammation panels.
• No endoscopy by default before the repeat stool/iron/CBC branch, unless red flags or persistent objective blood/iron signals appear.
• Lp(a)-specific drug access work unless imaging or approvals/trials make it actionable.
• Deep immune side quests unless repeat markers or symptoms point there.

Red flags that override the normal plan

Research trace

• Classification: INTEGRATE. The queue item had no single canonical owner and the output is a decision router that reduces cross-topic bloat.
• Research date: 2026-05-03.
• Personal context reviewed: refreshed cloud doc, current research queue, Lp(a), prevention status, recurrence action plan, occult stool blood, thrombocytosis, bloating-vs-bleeding, inflammatory-thrombotic axis, smoking/alcohol relapse, and 30-day experiment topics.
• Evidence anchors: EAS Lp(a) consensus and aortic-stenosis risk (PMID: 36036785); AHA/ACC chest pain guideline (PMID: 34709879); occult GI bleeding / IDA / CRC screening guidance (PMID: 23547576, 32810434, 34497146, 34003218); thrombocytosis investigation review (PMID: 38375212); health anxiety in chronic illness systematic review (PMID: 32716932); smoking/lifestyle risk context (PMID: 18362252, 37712231, 3565227, 15974805).
• Stop condition: a one-page hierarchy that changes routing and red-flag behavior without duplicating detailed topic pages.

Plan 30-Day Experiment

30-Day Healthy-Living Data Experiment

Summary

Status: completed; interpretation phase. The experiment ran 2026-04-26 at 14:00 -> 2026-05-26 at 14:00 Cambodia time. The planned no-coffee, tea-only final-week phase became a coffee-reduction / tea-substitution attempt with logged coffee exceptions from 2026-05-20 through the final labs; the earlier May 3-6 attempt remains a partial/interrupted exposure period.

Live cleanly and consistently for one month, log enough data to interpret the change, then compare end labs/stool results against the April baseline. This article is the clinical protocol and interpretation ledger; the Next Biomed Visit Plan remains the lab-logistics ledger.

The logging goal is meaningful long-term trends, not perfect symptom capture. Meals, exercise/walks, and stool photos are intended to be registered every time. Weak localized pains may be logged sporadically; stronger, new, persistent, or unusual pains matter more and should be logged when possible.

The experiment is not trying to prove one narrow mechanism. It is designed to separate four tracks that currently overlap: iron availability, occult blood, post-meal bloating/motility, and reactive inflammation/coagulation.

Current signal

Day-0 state from the first Tracker observation, 2026-04-26 14:28 Cambodia:

The 2026-04-19/20 blood and stool results remain the practical baseline for most markers: ferritin 54.01 with low serum iron 11.64, derived TSAT about 19%, normal hemoglobin 14.4, platelets 494, WBC 13.1, positive FOB/stool RBCs, and calprotectin normalized to 13.3.

Baseline Biomed day-0 testing is now logged across 2026-04-26/27. Key additions: reticulocyte 1.0% normal; fibrinogen 3.7 g/L high-normal; fasting glucose 99 mg/dL with insulin 4.4 µIU/mL gives HOMA-IR about 1.08; urine clean; IgG 1299 and IgM 72.5 normal; hemoglobin electrophoresis normal. The IgG/IgM/urine block is reassuring but is an IgA side quest, not the core experiment. Hemoglobin electrophoresis does not replace serum protein electrophoresis for the IgA band-pattern question.

A 2026-05-12 midpoint blood checkpoint has been added as directional context, not a clean comparator. Unlike the first experiment-day labs and the planned final labs, it was improvised around 14:00, roughly 1 hour after a meal and coffee. It is still useful: WBC normalized to 8.2, CRP stayed normal at 2.71, platelets improved to 452 but remain high, hemoglobin eased to 13.6, ferritin fell to 43.28, and TSAT improved to 27.7%. Interpret it as mid-experiment signal/noise.

The 2026-05-27/28 end summary is directionally better after the completed zero-alcohol/zero-smoking month and a final-week coffee-reduction/tea-substitution attempt. Blood-side: ferritin rose to 61.60, TSAT recovered to 33.4%, WBC stayed normalized at 7.7, CRP stayed normal at 2.52, and platelets improved to 444 — just below the common 450 thrombocytosis threshold but still above Biomed's reference range. Stool-side: FOB became negative and stool RBCs were absent on 2026-05-28. This strengthens the practical hypothesis that alcohol-plus-smoking periods destabilize gut symptoms, iron recovery, and reactive/inflammatory markers, and it cools the April occult-blood branch. It does not prove alcohol alone caused the April positive stool test, and recurrence rules still apply if visible blood, iron decline, or repeat stool positivity returns.

Tracker context before the final-week phase: coffee was still being logged through 2026-05-19, and 2026-05-12/13/15 observations linked coffee temporally with bloating or brief abdominal pain. The final-week log then shows tea substitution plus coffee exceptions on 2026-05-21, 2026-05-23, 2026-05-24, 2026-05-25, and 2026-05-26. That does not prove coffee is causal, and it means the final-week phase must be analyzed as reduced coffee with exceptions — not as a clean coffee-free trial.

Decision questions

Protocol rules

A slip is data. Log it and continue; do not restart the clock unless the month becomes too noisy to interpret.

Tracker logging

Use the Tracker app as the experiment log, not as a nutrition calculator: https://spinningowl.cloud/meal-tracker/.

The app already handles timestamps, offline queueing, photo upload, experiment counter, and export. Those implementation details belong to the app, not this clinical protocol.

Apple Watch setup for cleaner data

The useful signal is repeatable overnight and walking data, not more metrics. Assume default settings are fine unless data are missing.

1. Sleep/Vitals: no fixed sleep schedule needed. When lying down, turn on Sleep Focus manually from iPhone Control Center -> Focus -> Sleep, or Apple Watch side button -> Control Center -> Focus -> Sleep. Turn it off on waking. Vitals needs about 7 worn nights to establish a range.
2. Track sleep only if data are missing: Apple Watch app -> My Watch -> Sleep -> Track Sleep with Apple Watch. Do not check this routinely; it is usually already on if sleep tracking works.
3. Runkeeper is fine for walks/exercise if Health Sync is on. One-time verify after the next walk: Health app -> Search -> Workouts -> Show All Data -> latest workout should list Runkeeper and show duration/distance; if it has route/HR/active energy, even better. Do not double-track the same walk in Apple Workout unless testing.
4. Walk accuracy one-time check only if pace/distance look wrong: iPhone Settings -> Privacy & Security -> Location Services -> System Services -> Motion Calibration & Distance. If on, stop checking. Apple’s formal calibration method is one 20-minute Apple Workout -> Outdoor Walk on a flat/open route.
5. Benchmark walks: for deliberate walks, use Runkeeper consistently and reuse the same route when practical; compare pace vs average HR over weeks.

Do not spend time auditing default privacy/heart-rate settings unless resting HR, walking HR, workout HR, or sleep data are missing. Apple does not offer a useful setting to increase passive measurement frequency. The practical frequency boost is workout tracking: Apple measures HR continuously during Workout app sessions; Runkeeper is acceptable if its workout in Health includes HR. Avoid Low Power Mode during sleep/workouts because it disables background HR/blood-oxygen measurements and heart notifications.

Manual sensors: take one calm baseline ECG if the app is already set up, then use ECG only for palpitations, skipped/rapid heartbeat, chest discomfort, dizziness, unusual shortness of breath, or an irregular-rhythm notification. ECG is a 30-second single-lead rhythm snapshot and does not detect heart attack, stroke, clots, cholesterol, or blood pressure. Optional blood-oxygen/current-HR checks are symptom-timed only. Skip sleep-stage micromanagement and daily HRV rituals unless effortless.

Log only context Apple/Runkeeper cannot know: tea type/size and any coffee slip, smoking/alcohol slips, illness, gut symptoms, and unusual stress/sleep.

Abdomen circumference

Use the tape as an objective distension add-on. The 0-10 bloating score captures pressure/discomfort; maximum-width abdomen circumference captures physical expansion.

Protocol:

1. Stand upright and relaxed.
2. Let the abdomen relax normally; do not suck in or push out.
3. Wrap the tape horizontally around the widest belly point at that moment.
4. Measure after a normal relaxed exhale.
5. Use snug contact without compression.
6. Record to nearest 0.5 cm if possible, otherwise nearest 1 cm.
7. Use short notes: max-width abdomen 92.5 cm, standing relaxed.

Best comparison points: morning baseline after toilet and before food/tea; symptom peak; about 2 hours after a main meal. Interpret the delta more than the absolute number. A +5 cm symptom-peak rise supports physical distension; a high bloating score without much circumference change points more toward visceral sensitivity/pressure.

This stays in the symptom/motility branch. It does not replace the bleeding dashboard: visible blood, FOB/stool RBC, ferritin/TSAT/Hb, and red-flag symptoms.

Fasting branch — deferred until after final labs

Classification: WATCH / optional later self-test, not a core intervention. Fasting was reviewed as a queued 24h/48h/72h idea for the active 30-day window. It was correctly not added before day-30/31 labs. The practical conclusion remains conservative: protect the clean signals from smoking abstinence, alcohol abstinence, meal timing, stool/iron follow-up, Apple Watch/BP context, and the weaker final-week coffee-reduction signal. A later 24-hour fast can answer a gut-motility question, but it should not become a major health-optimization project during this loaded protocol.

What fasting can plausibly help interpret: meal-driven bloating, MMC/no-snacking response, walking-related distension when fasted, refeed sensitivity, resting HR/HRV/sleep, and behavioral stability under food absence.

What it should not be used to interpret: occult-blood clearance, iron-loss source, diverticular rebleeding prevention, cancer screening, Lp(a) risk, aspirin/antithrombotic safety, or whether WBC/platelets are reactive versus clonal.

If a 24h fast is done, log start/end time, water/electrolytes/salt use, hunger/cravings, bloating and maximum-width abdomen circumference at baseline/pre-refeed/2h post-refeed, fasted walk response, stool/photo if any, sleep, resting HR/HRV, optional BP, and the first refeed meal. Refeed with a moderate familiar vegetarian meal; avoid a huge spicy/oily/raw-fiber challenge. Stop early for dizziness/fainting, chest pain, palpitations, unusual shortness of breath, severe weakness/confusion, severe abdominal pain, visible red/maroon/black stool, vomiting, or inability to hydrate.

Evidence anchors: prolonged fasting review (PMID: 37377031); intermittent-fasting RCT meta-analysis (PMID: 40533200); 48h cognition/mood studies (PMIDs: 28025637, 32504694); 72h metabolic studies (PMIDs: 30183740, 12388154); supervised fasting safety cohorts (PMIDs: 29458369, 30601864); prolonged fasting inflammation/platelet activation signal (PMID: 40268190).

Stool photos

Goal: make images comparable enough for later stool consistency/color review. Consistency matters more than perfect images.

Historical comparator: two user-supplied stool photos timestamped 2025-08-20 have been archived privately under the local archive identifier stool-photos-2025-08-20. They may represent the actual late-August 2025 visible bleeding incident or an immediately adjacent stool. Do not publish the images; use the private originals and manifest only as a later comparator for visible blood/color patterns when reviewing 30-day Tracker stool photos or stool-blood research.

Historical exposure context: a separate private archive, topical-mupirocin-prebleed-2025-08, records the user-supplied photo of 康立邦 莫匹罗星软膏 (mupirocin ointment), reported as bought OTC and applied to penile/genital skin before the August 2025 bleeding incident. The front panel shows 5 g and external-use OTC markers; matching listings show 2% (20 mg/g). Use this later as exposure context when comparing the historical bleed with current stool-photo/stool-blood data; do not treat it as causal until researched.

Practical default: same conditions, straight above, flash on, focused on the toilet bowl contents, stool as large as practical in the frame.

Final-week sub-experiment — coffee-reduction tea phase

The deliberate coffee-removal plan started on 2026-05-20, but the actual Tracker record shows a coffee-reduction / tea-substitution phase with exceptions, not a clean coffee-free trial. Logged final-week coffee exceptions were 2026-05-21 (“Coffee”), 2026-05-23 (“Coffee”), 2026-05-24 (“Tuna bun and coffee”), 2026-05-25 (“Coffee”), and 2026-05-26 (“Daily coffee before working”). The original 2026-05-03 14:00 -> 2026-05-10 14:00 Cambodia time window was paused/postponed as of 2026-05-06 because nicotine/smoking abstinence was the higher-priority experiment load. Treat May 3-6 as logged context and May 20-26 as reduced coffee with exceptions, not as a clean no-coffee comparator.

Final-phase interpretation default: not a clean no-coffee trial. It can still inform whether reducing coffee and substituting tea was behaviorally feasible and whether clearly tea-only days differed from coffee-exception days. Recommended default remains useful if the habit continues: green tea or oolong earlier in the day; rooibos/ginger/chamomile/lemongrass/chrysanthemum later, with tea kept away from iron-focused meals when practical. Keep meals, alcohol/smoking abstinence, exercise, and other routines stable when evaluating any future coffee-removal signal.

What it can answer now: whether reduced coffee plus more tea coincided with any obvious change, and whether tea-only days differ from coffee-exception days. What it cannot answer cleanly: whether strict coffee removal improves bloating, stool/urgency changes, sleep/HR signals, or iron-absorption noise. A future clean trial would need no coffee at all and no cola/diet-soda replacement, because carbonation, phosphoric acid/cola flavoring, caffeine, and non-caloric sweeteners are separate GI variables.

Evidence basis kept practical: brewed coffee is roughly 96 mg caffeine per 8 oz, green tea about 29 mg, and black tea about 48 mg, with wide preparation variability (Mayo Clinic, 2025). Caffeine withdrawal can begin 12-24 hours after stopping, peak around 20-51 hours, and last 2-9 days, sometimes from habitual intakes around 100 mg/day (PMID: 15448977); therefore a tea-caffeine allowance keeps withdrawal from drowning the coffee-specific signal. Iron timing still matters because polyphenol-containing drinks, including black tea, coffee, peppermint, and several herbal teas, can strongly inhibit non-heme iron absorption with a meal (PMID: 10999016). Coffee also has GI effects beyond caffeine, including gastric-acid/gastrin, bile/pancreatic secretion, microbiome, and colonic-motility effects, with individual symptom response still variable (Nutrients 2022 coffee-GI review, PMCID: PMC8778943).

End tests

At day 30/31 (2026-05-26/27 Cambodia), repeat the paired set if possible.

Blood:

• CBC/Hg
• Reticulocyte
• Ferritin
• Iron
• TIBC
• Fibrinogen
• CRP hs or CRP
• ESR
• Fasting glucose + fasting insulin if taken at day 0
• Homocysteine + folate only if taken at day 0 and the month included meaningful diet/supplement/alcohol changes

Stool:

• Essential: FOB + Stool Direct Exam = $9.50
• Better full context: FOB + Stool Direct Exam + Calprotectin = $74.50 if inflammatory symptoms return or the GI picture is unclear
• Optional: H. pylori stool antigen (+$15) only if upper-GI suspicion increases

Optional blood add-ons only if the result would change interpretation: zinc ($16.25) and copper ($15.00, especially if adding zinc). CEA is not a routine stool-blood add-on; use it only if a clinician specifically wants tumor-marker follow-up in the context of prior CEA history, symptoms, imaging, or endoscopy planning.

If visible blood, melena, worsening pain, dizziness, unusual fatigue, or a major bowel-pattern change appears, do not wait for day 30. Repeat the stool/blood set sooner and treat it as a GI-source escalation question.

Interpretation

Blind spots

These remain separate tracks even if the month goes well:

• persistent positive occult blood still needs GI-source logic
• poor iron response may need celiac/malabsorption reassessment
• persistent bloating may still need SIBO/breath-testing workup
• persistent thrombocytosis may still need JAK2/CALR/MPL-style escalation logic
• Lp(a), BP, and cardiac imaging are separate risk-management tracks

Plan Post-Experiment Decision Router

thirty-day-experiment · post-experiment-router · stool-blood · iron · thrombocytosis · bloating · lp(a) · bp · imaging · treatment-priority

Post-Experiment Decision Router

This is the single current router for post-experiment decisions. The older exam-plan, treatment-priority, and knowledge-roadmap material has been consolidated here so the reader does not have to cross-check multiple planning pages.

Current conclusion

Do not decide from one symptom day or order a broad “Round 2” panel. The completed clean-month result is encouraging — ferritin/TSAT recovered, WBC normalized, platelets improved to 444, and repeat stool FOB/RBC cleared — but the next branch still depends on objective persistence/recurrence:

1. red flags override everything;
2. final blood + stool now cool the GI/iron branch; logs/BP/wearables define the remaining branch weights;
3. cardiac risk gets BP + echo/CAC/CCTA anchoring regardless of GI symptom noise, especially now that old papers document mild peripheral plaque;
4. recurrent stool blood/iron drift drives GI-source planning;
5. persistent platelets/WBC drive CBC differential/smear then hematology logic;
6. bloating/motility is treated as a symptom branch, not as proof for or against bleeding;
7. low-yield novelty tests stay parked unless a branch activates them.

What changes the decision

What to do now

Treatment priority after results

What not to do

Evidence and owner links

• Emergency routing owners: Whole-Profile Seriousness Triage, Recurrence Action Plan.
• Bleeding/iron owners: GI Bleeding / Diverticular / Stool Blood, Iron, B12 & Malabsorption.
• CBC/hematology owners: Thrombocytosis Workup Pathway, Inflammatory-Thrombotic Axis.
• Cardiac owners: ASCVD / Lp(a) Prevention Master, Cardiac Imaging & Valve Plan, Blood Pressure Profile.
• Symptom owner: Bloating / Motility / SUDD-SIBO Symptom Plan.
• IgA owner: Elevated IgA Workup.
• Local logistics owner: Phnom Penh Medical Access.

Research anchors retained here include AGA/BSG iron-deficiency guidance, AGA bloating guidance, AHA/ACC chest-pain guidance, EAS Lp(a) consensus, thrombocytosis reviews, ACG celiac/H. pylori guidance, BP/LDL/smoking/alcohol outcome evidence, MASLD FIB-4/VCTE thresholds, CAP monoclonal-gammopathy lab guidance, KDIGO CKD baseline logic, AUA/SUO PSA repeat-test principle, and prolonged-fasting safety/noise evidence. The migration manifest tracks provenance/checksums.

Plan Research Queue

planning · future work

Research Queue

Research topics queued for investigation. Items are prioritized by clinical relevance. When you ask me to "do some research" or "research N items", I work through this list top to bottom.

Priority 1 — High Clinical Urgency

No active Priority 1 item after the medication/supplement safety-reference audit was completed on 2026-05-08.

Priority 2 — Actionable Soon

Platelet persistence: cause attribution and reduction strategy

• status: active
• owner topics: Thrombocytosis Workup Pathway, Inflammatory-Thrombotic Axis, Iron / B12 / Malabsorption, GI Bleeding / Diverticular / Stool Blood, and Medication List + Hard Avoids
• decision target: research why platelet counts have stayed borderline/high over years in Dag's profile, which explanations are most likely after the clean-month improvement, and which actions can realistically lower platelets versus only reduce thrombotic risk.
• why it matters: platelets improved but remain above Biomed's reference range and near the common thrombocytosis threshold, while WBC normalized and stool/iron signals cooled. The unresolved question is whether this is residual reactive thrombocytosis, a persistent source such as iron loss/inflammation/smoking/oral-skin-gut disease, lab/physiologic baseline, or a clonal/myeloproliferative branch that needs focused testing.
• research scope: review reactive thrombocytosis algorithms, expected platelet response after smoking cessation, iron repletion, bleeding resolution, infection/inflammation control, skin/oral/gut source cleanup, exercise/weight/BP/ApoB risk reduction, medications/supplements that do or do not lower platelet counts, antiplatelet boundaries with GI-bleed risk, and thresholds for smear, JAK2/CALR/MPL, BCR-ABL1, hematology, marrow, or myeloid/CHIP sequencing.
• integration threshold: integrate only if the research changes the current platelet pathway: repeat-test timing, which reactive sources to prioritize, what counts as a meaningful fall, what not to self-treat, when to ask hematology for mutation testing, or how to separate platelet-lowering from cardiovascular-risk lowering.
• stop condition: owner pages give a practical "what lowers platelets / what only lowers risk / what requires hematology" table, with triggers for watch-only, reactive-source cleanup, smear/molecular workup, and urgent escalation.

Unified gut-symptom mechanism map: bloating, stool changes, bleeding, iron, CBC

• status: active
• owner topics: GI Bleeding / Diverticular / Stool Blood, Bloating / Motility, Iron / B12 / Malabsorption, Inflammatory-Thrombotic Axis, and Whole-Profile Seriousness Triage
• decision target: deep-research whether the apparently parallel gut problems are better explained by one connected model or by separate branches that only cluster through shared exposures.
• why it matters: Dag's lived pattern is that extreme bloating, stool/spot-pain changes, bleeding/occult blood concern, iron recovery, and CBC/inflammatory markers seem to move in the same broad period. The current KB separates symptom/motility and bleeding mechanisms to avoid unsafe inference; this item asks whether a higher-level synthesis can connect them without erasing the red-flag boundaries.
• research scope: review diverticular disease/SUDD, post-diverticular visceral hypersensitivity, dysbiosis/SIBO/MMC, gut-barrier injury, alcohol/smoking effects, occult bleeding/iron physiology, calprotectin-negative bleeding, mast-cell/eczema/allergic gut links, autonomic/stress mechanisms, and inflammatory-thrombotic marker coupling; map each candidate against Dag's timeline and objective data.
• integration threshold: produce a compact connected-mechanism model only if it changes decisions, for example test sequencing, symptom logging, exposure priorities, or escalation thresholds; otherwise preserve the current separated-branch safety model with clearer cross-links.
• stop condition: owner pages explicitly state which symptoms can plausibly share upstream drivers and which findings still require independent evaluation: visible/occult blood, ferritin/TSAT/Hb drift, melena, persistent focal pain, or CBC abnormalities.

Undigested-food fragment and mixed-consistency stool triage

• status: active
• owner topics: Bloating / Motility, Iron / B12 / Malabsorption, GI Bleeding / Diverticular / Stool Blood, and Whole-Profile Seriousness Triage
• decision target: determine whether an occasional visibly undigested pale food fragment plus one same-sample mix of hard/dark stool and pale/liquid stool should change the current GI interpretation, stool logging, or post-experiment test router.
• why it matters: a single larger fragment found only while preparing a stool sample may be benign food identity / chewing / high-fiber or rapid-transit noise, but in Dag's profile it sits near open questions about bloating, motility/SUDD-SIBO, occult stool blood, iron recovery, and possible malabsorption. The research should prevent over-reading one observation while defining the threshold where recurrence becomes meaningful.
• research scope: review normal visible food remnants versus pathologic steatorrhea/maldigestion; rapid transit, IBS/SUDD, bile-acid diarrhea, pancreatic exocrine insufficiency, celiac disease, small-bowel disease, and diet/meal-size/chewing contributors; map which stool features are visually useful versus unreliable; define logging prompts and test triggers such as weight loss, persistent diarrhea/greasy floating stool, recurrent large undigested fragments, worsening iron/B12/ferritin patterns, or persistent stool-blood positivity.
• integration threshold: integrate only if the evidence changes practical rules in the motility/malabsorption/stool-blood owners, such as when to escalate from observation to celiac/pancreatic/BAD evaluation or how to tag mixed-consistency stools in the tracker/photo protocol.
• stop condition: owner pages state whether this pattern is watch-only after a one-off observation, which recurrence/red-flag features would make it clinically useful, and how it interacts with the existing occult-blood/iron branches.

Priority 3 — Monitor and Plan

CEA / tumor-marker role cleanup

• status: active
• owner topics: 30-Day Experiment, Post-Experiment Decision Router, and any future test-order page
• decision target: ensure CEA is not treated as routine CRC screening or a reflex stool-blood add-on.
• why it matters: prior CEA history is real, but CEA has poor screening/diagnostic performance and should not distract from stool blood, iron, symptoms, imaging, or endoscopy-quality logic.
• integration threshold: keep CEA only as clinician-directed follow-up in context of prior CEA trend, symptoms, imaging, or endoscopy planning.
• stop condition: no active plan text recommends routine CEA because FOB remains positive.

Priority 4 — Parking Lot / Only If It Becomes Actionable

Periodic Lp(a) therapy/trial watchlist refresh

• status: watch
• owner topics: Lp(a) Therapy Watchlist
• decision target: keep pelacarsen, olpasiran, lepodisiran, muvalaplin, zerlasiran, PCSK9-bridge logic, and Norway/SE Asia access status current without bloating the page.
• trigger: new phase-3 outcome readout, regulatory filing/approval, new Southeast Asia/Norway recruiting site, or next scheduled watchlist review.
• integration threshold: update approval/trial/access status only if it changes practical readiness, clinician discussion, or sourcing; otherwise add a one-line reviewed/no-change note.
• stop condition: next_review date set in the owner topic after each refresh.

Completed research

Completed and de-prioritized research items are no longer part of the active reading surface. Current conclusions should live in the owner topics above; this queue should stay small: unresolved decision-changing questions, watch triggers, and no large completion ledger. The migration manifest tracks the preservation file/checksum for the completed ledger.

• 2026-05-24: daily cannabis / dry-herb vaping risk at 20 g/week researched and folded into Daily Cannabis / Dry-Herb Vaping Risk; active queue item closed immediately after integration.

Urgent ASCVD / Lp(a) Prevention Master

cardiovascular · lp(a) · ascvd · prevention-status · apob · aspirin · pcsk9 · hdl · smoking · bleeding-risk

ASCVD / Lp(a) Prevention Master

This is the single current owner for Lp(a), prevention tier, HDL context, and aspirin/antithrombotic boundaries.

Current conclusion

Lp(a) is the stable cardiovascular risk anchor: 838.6 mg/L (reference <250 mg/L), roughly 83.9 mg/dL by simple division but not reliably convertible to nmol/L because apo(a) isoform size and assay method matter. Preserve the raw value/unit; use nmol/L if a future lab can report it directly.

Old RPPH papers found in June 2026 document right common-femoral artery atherosclerosis / mild PAD on 2024-01-22 Doppler: mixed plaque with 24-31% CFA stenosis, thin calcified/soft plaque in SFA/popliteal artery without significant stenosis, and no distal tibioperoneal/ATA/PTA stenosis. The certificate called it an incidental finding that might not explain the hip/leg symptom, but it is still objective extracoronary atherosclerosis. Archive ID: rpph-2024-01-22-cardiology-orthopedic-papers.

Coronary and aortic-valve burden remain unknown until CAC/CCTA/echo. The prevention label should therefore avoid two errors: not “risk-factor only / no documented disease” anymore, but also not automatically post-MI secondary prevention. Treat this as documented mild peripheral atherosclerosis with unresolved coronary/valve staging.

The action is not “lower Lp(a) with lifestyle.” Lp(a) is mostly genetic. The action is: treat every modifiable risk driver harder than a standard calculator would suggest, define coronary/valve burden, and avoid adding bleeding-risk drugs without a real indication.

What changes the decision

What to do now

What not to do

Evidence and owner links

• Imaging/valve owner: Cardiac Imaging & Valve Plan.
• Therapy pipeline owner: Lp(a) Therapy Watchlist.
• BP owner: Blood Pressure Profile, BP / Sleep-Apnea.
• Bleeding safety owner: GI Bleeding / Diverticular / Stool Blood, Medication List + Hard Avoids.
• Smoking/alcohol owner: Smoking + Alcohol Relapse Risk.
• CBC/thrombotic context owner: Thrombocytosis Workup, Inflammatory-Thrombotic Axis.

Evidence anchors include private source abstraction rpph-2024-01-22-cardiology-orthopedic-papers; EAS/consensus Lp(a) risk evidence (PMID: 36036785; PMID: 41381044; PMID: 41899103), ACC/AHA primary prevention and aspirin limits (PMID: 30879355), chronic coronary disease / CCTA risk-tier framing (PMID: 37471501; PMID: 39210710), ESC/EAS lipid-intensification context (PMID: 41785983), aspirin/high-Lp(a) subgroup evidence and bleeding uncertainty (PMID: 18775538; PMID: 36175048; PMID: 38293935; PMID: 39191359; PMID: 30667501; PMID: 35471505), recurrent diverticular hemorrhage antiplatelet concern (PMCID: PMC6219900), and HDL U-curve/function evidence (PMID: 41618310; PMID: 41284745; PMID: 40443511; PMID: 35583863; PMID: 40858201; PMID: 41618471).

Urgent Recurrence Action Plan

cardiovascular · emergency-action-plan · chest-pain · epigastric-pain · troponin · ECG · lp(a)

Recurrence Action Plan for Early-April 2025 Pain Episode

SearchPlan

• Question type: clinical decision synthesis / emergency action rule.
• Question: If the early-April 2025 cluster recurs, when should it trigger immediate cardiac rule-out rather than retrospective GI speculation?
• Dag-specific context: male 51, Lp(a) 838.6 mg/L, active/recent smoking, no documented CAD yet, prior episode described as sudden intense abdominal/epigastric pain with dizziness, heavy sweating, and left hand/lower-arm cramping-vibration symptoms.
• Sources searched: live cloud doc, existing KB cardiovascular/GI topics, 2021 AHA/ACC chest pain guidance, NICE recent-onset chest pain guidance.
• Stop condition: a practical if/then plan short enough to use during a recurrence.

Core Rule

If the same pattern recurs, treat it as possible acute coronary syndrome until same-day ECG + high-sensitivity troponin assessment rules it out:

• sudden intense chest, epigastric, upper-abdominal, jaw, shoulder, back, or left arm/hand discomfort
• plus sweating, dizziness, faintness, nausea, shortness of breath, palpitations, unusual weakness, or a sense that something is seriously wrong
• especially if it occurs during/after exertion, smoking, alcohol, poor sleep, dehydration, or acute stress

Do not wait to see whether it becomes typical chest pain. Atypical location does not make it safe; epigastric/upper-abdominal pain can be an ischemic presentation.

Action Plan During Symptoms

1. Stop activity immediately. Sit or lie down. Do not continue walking/jogging to “test it.”
2. Call / go to emergency care if symptoms are severe, persistent, recurrent, or accompanied by sweating/dizziness/arm symptoms. Do not self-triage as bloating.
3. Ask specifically for ECG + high-sensitivity troponin. A single normal ECG is not enough if symptoms were recent; troponin timing/serial testing matters.
4. Bring / show the risk summary: Lp(a) 838.6 mg/L, active/recent smoking, atorvastatin use, no aspirin because diverticular bleeding/occult blood, prior similar episode.
5. Avoid aspirin self-start unless emergency clinician advises it. This profile has real GI bleeding risk; antiplatelet decisions belong to the clinician evaluating a possible ACS event.
6. If symptoms fully resolved but were convincing, same-day urgent ECG/troponin assessment is still reasonable rather than waiting weeks and trying to interpret it from memory.

What Counts as “Convincing Enough”

After a Negative Acute Rule-Out

If ECG/troponin rule out acute MI but the symptom pattern remains concerning, the next question becomes coronary anatomy / ischemia, not reassurance-by-default:

• cardiology review
• CAC if still doing low-friction baseline risk anchoring
• CCTA if symptoms recur, clinician concern persists, or direct plaque/stenosis assessment would change management
• echo baseline for Lp(a)-linked aortic valve disease and LV function

Evidence Layer

• 2021 AHA/ACC chest pain guidance covers acute and stable chest pain evaluation and emphasizes structured risk assessment, ECG, troponin, and appropriate cardiac imaging/testing when ischemia is possible (PMID: 34709879).
• NICE recent-onset chest pain guidance similarly centers rapid diagnosis using ECG, high-sensitivity troponin, CT coronary angiography, and functional testing when cardiac origin is suspected (NICE CG95).
• Existing KB risk context: Lp(a) 838.6 mg/L and smoking raise the cost of missing ACS; diverticular bleeding raises the cost of casual aspirin.

Key Takeaways for This Profile

1. The recurrence rule is simple: epigastric/upper-abdominal pain + sweating/dizziness/left arm-hand symptoms = cardiac rule-out now.
2. GI bloating does not produce a free pass when autonomic symptoms and arm/hand symptoms are present.
3. The minimum useful acute workup is ECG + high-sensitivity troponin with appropriate timing/serial interpretation.
4. Do not self-start aspirin in this profile unless emergency clinicians direct it.
5. If acute MI is ruled out but symptoms recur, CCTA/cardiology becomes the more relevant next step than another retrospective GI theory.

Research Trace

• Research date: 2026-04-27.
• Sources searched: cloud doc, KB cardiac/GI topics, ACC/AHA chest pain guidance, NICE CG95.
• Query summary: epigastric/chest pain + diaphoresis/dizziness/left arm symptoms; ECG/troponin emergency rule-out; recent-onset chest pain guidance.
• Evidence anchors: PMID: 34709879; NICE CG95.
• Unresolved gap: exact fastest Phnom Penh facility for ECG + hs-troponin pathway.

Important Lp(a) Therapy Watchlist

lp(a) · cardiovascular · emerging-therapy · pelacarsen · olpasiran · muvalaplin · lepodisiran · zerlasiran · pcsk9

Lp(a) Therapy Watchlist and Readiness Plan

SearchPlan

• Question type: watchlist / future-therapy tracking.
• Question: Which Lp(a)-lowering therapies matter in 2026, what milestones are pending, and what can actually be pursued in Southeast Asia or Norway now?
• Dag-specific context: Lp(a) 838.6 mg/L, old RPPH papers now document mild right common-femoral plaque/PAD on 2024-01-22, ApoB/LDL already fairly controlled on atorvastatin 20 mg, bleeding risk makes aspirin unattractive, coronary/valve imaging status unknown.
• Sources searched: PubMed/ACC summaries, ClinicalTrials.gov API, sponsor/official trial pages, existing KB Lp(a)/imaging topics.
• Stop condition: concise active watchlist with phase/status, milestone, and management implication.

Current Readiness Rule

Do not wait passively for Lp(a) drugs, but do not pretend they are ready either. The actionable preparation is:

1. Document actual disease burden: the 2024 Doppler already documents mild peripheral plaque; CAC/CCTA/echo decide whether there is coronary plaque, chronic coronary disease, or valve disease.
2. Keep ApoB/LDL low now: Lp(a)-specific therapy will likely be added on top of standard risk-factor control, not replace it.
3. Control the high-ROI modifiers: smoking cessation and blood-pressure profile probably matter more today than any supplement or speculative off-label move.
4. Use PCSK9 inhibitors as the current bridge discussion if cardiology treats the documented peripheral plaque/high Lp(a) as enough risk, if coronary imaging documents plaque, or if very-high-risk LDL/ApoB targets are chosen.
5. Track outcomes, not biomarker hype: 80-95% Lp(a) reduction is impressive, but event reduction, approval label, access, and cost decide practice.

Therapy Watchlist

Trial Status Anchors Checked 2026-05-04

Access Map Checked 2026-05-04

Current classification: WATCH / no active sourcing action. The near-term action remains disease-burden documentation and standard prevention optimization, not trial-chasing. Re-check trial geography after the pelacarsen readout/regulatory filings or if a new recruiting primary-prevention trial opens in Norway/Singapore/Thailand.

Dag-Specific Implications

• Known mild peripheral plaque/PAD (2024 Doppler): strengthens standard prevention intensity and PCSK9-bridge discussion, but does not by itself create an available Lp(a)-specific therapy route.
• If no coronary plaque / CAC=0 / normal echo: peripheral plaque still matters, but first Lp(a)-specific labels may still focus on established CVD definitions; cardiology wording matters.
• If CAC>0 or CCTA coronary plaque: the argument for PCSK9 bridge therapy and very aggressive ApoB/LDL targets strengthens further while waiting for Lp(a)-specific approval.
• If obstructive CAD / chronic coronary disease: Lp(a)-specific therapy becomes much more likely to fit early approval labels if outcomes trials are positive.
• If aortic valve sclerosis/stenosis is present: track whether outcome programs include valve endpoints or whether separate valve-focused evidence emerges; do not assume ASCVD outcome benefit automatically solves valve disease.
• Aspirin remains separate: Lp(a) therapy watchlist does not change the current no-aspirin primary-prevention rule while GI bleeding risk is unresolved.

What to Watch Next

1. Pelacarsen HORIZON readout: first major yes/no test for whether large Lp(a) lowering reduces events.
2. Regulatory label wording: established ASCVD only vs broader high-risk primary prevention; Lp(a) threshold; LDL/ApoB requirements; safety exclusions.
3. OCEAN(a)-Outcomes and ACCLAIM-Lp(a): confirm whether siRNA class effects translate to outcomes.
4. OCEAN(a)-PreEvent: most relevant to people before a first major event, but not near-term.
5. Local/regional access after approval or a relevant recruiting trial: the 2026-05-04 check found no approved Lp(a)-specific drug and no currently recruiting Southeast Asia/Norway therapeutic trial suitable for this profile; the newly found mild PAD record does not change access today.

Key Takeaways for This Profile

1. Lp(a)-specific therapy is plausible soon, but not actionable until outcomes/approval/access exist.
2. Pelacarsen is the near-term event-readout to watch; olpasiran and lepodisiran are larger later outcomes anchors.
3. Muvalaplin is important because it is oral, but still biomarker-stage.
4. PCSK9 inhibitors remain the only current pharmacologic bridge with both ApoB/LDL lowering and modest Lp(a) lowering.
5. The 2026-05-04 access check says: no trial-chasing now. Norway has closed/not-recruiting ASCVD trials; Singapore/Thailand have no current suitable therapeutic Lp(a) trial found.

Research Trace

• Research date: 2026-05-04.
• Sources searched: ClinicalTrials.gov API, PubMed review/current-status pass, ACC/trial summaries, sponsor/official trial pages, existing KB Lp(a)/imaging topics.
• Query summary: pelacarsen HORIZON NCT04023552; olpasiran OCEAN(a)-Outcomes / PreEvent; muvalaplin KRAKEN; lepodisiran ALPACA / ACCLAIM; zerlasiran ALPACAR; country filters for Norway, Thailand, Singapore.
• Evidence anchors: ClinicalTrials.gov NCT04023552, NCT05581303, NCT07136012, NCT05565742, NCT06292013; Singapore signals NCT04914546, NCT07177612, NCT06304415; Thailand completed observational signal NCT03887520; current-status review PMID: 40430570; PCSK9/Lp(a) review evidence PMID: 41549171, PMID: 41175045, PMID: 40841123; pelacarsen/olpasiran/pipeline anchors PMID: 41102962, PMID: 41879443, PMID: 40821459.
• Open gaps: outcome results, approval labels, cost/access, whether primary-prevention high-Lp(a) without plaque qualifies, and whether Norway/Singapore/Thailand gain recruiting primary-prevention trials or early-access routes after regulatory filings.

Important Smoking + Alcohol Relapse Risk

smoking · alcohol · lipoprotein-a · ascvd · inflammation · thirty-day-experiment

Smoking + Alcohol Relapse: Lp(a), ASCVD, and Gut Risk

Bottom line

Stopping smoking and alcohol is not expected to substantially lower the measured Lp(a) number itself. That is the wrong target.

The clinically important point is that Dag already has a fixed high-risk Lp(a) background. Smoking and alcohol add modifiable risk through other channels:

• smoking: endothelial injury, oxidative stress, vasoconstriction, platelet/coagulation activation, higher fibrinogen, inflammation, and direct ASCVD risk
• alcohol relapse: higher blood pressure, poorer sleep/HRV, atrial-arrhythmia risk, gut-barrier irritation, gastritis/bleeding risk, poorer food choices, and worse adherence to the experiment
• both together: worse signal quality during the 30-day trial and harder interpretation of BP, gut symptoms, inflammatory markers, and stool-blood/iron trends

So the operational rule is simple: treat smoking abstinence as the highest-ROI behavior target in the Lp(a) plan, and treat alcohol avoidance as a high-value intervention while the stool-blood/iron/CBC branch is unresolved. The new late-2025 context changes the interpretation of that period: ferritin 35.28 on 2025-12-22 occurred during likely heavy alcohol/cigarette exposure, but the 2025-12-23 stool occult blood/RBC test was negative, so December supports “iron-store depletion during destabilizing exposure,” not proven active bleeding at that moment. April 2026 is different: stool occult blood was positive and stool RBCs were present, with alcohol/smoking back in the wider period but exact timing relative to the stool sample not proven.

Lp(a): probably stable; risk context is not stable

Lp(a) has little correlation with standard risk factors and is highly consistent over time. In the Reykjavik prospective data, Lp(a) showed a high regression-dilution ratio over 12 years and predicted coronary heart disease after adjustment for smoking, blood pressure, cholesterol, triglycerides, diabetes, and BMI. That supports the practical framing: lifestyle changes do not erase the Lp(a) baseline. [PMID: 18362252]

But that does not make lifestyle irrelevant. A 2024 clinical cohort found both Lp(a) and an unfavorable lifestyle score were associated with CAD; the lifestyle score remained associated with CAD independent of Lp(a). This is the key message for this profile: high Lp(a) makes the margin for avoidable risks smaller, not larger. [PMID: 37712231]

Smoking: the main modifiable risk multiplier

Smoking should be treated as a direct cardiovascular-risk amplifier even if the Lp(a) number does not move much.

Mechanisms relevant to Dag's current marker pattern:

• raises inflammatory markers and white-cell activation
• raises fibrinogen and promotes a prothrombotic state
• worsens endothelial function and plaque vulnerability
• interacts poorly with high Lp(a), because both push plaque biology and thrombosis/inflammation in the wrong direction

Framingham data linked smoking with higher fibrinogen, showed ex-smokers with fibrinogen values as low as non-smokers, and found fibrinogen contributed to cardiovascular risk even after accounting for smoking and standard risk factors. [PMID: 3565227]

NHANES III showed dose-dependent and time-related improvement in inflammatory and traditional cardiovascular risk factors after smoking cessation. Smoking-specific WBC studies make the CBC link concrete: current smoking is a reversible cause of higher WBC and differentials, and biochemically confirmed abstinence can lower WBC and absolute neutrophils within weeks to months. In one cessation trial, continuous abstinence was associated with about a 1.2 x 10^9/L larger WBC drop and about a 1.0 x 10^9/L larger ANC drop by 52 weeks than continued smoking. The important practical implication is that the clean month can plausibly improve WBC/neutrophils before Lp(a) itself changes. [PMID: 15974805; PMID: 16092581; PMID: 27583199]

WBC / neutrophil correlation note

Interpret WBC dates against smoking exposure before escalating the leukocytosis branch. Current smoking is a strong candidate for neutrophil-weighted leukocytosis, but it is not a complete explanation unless the personal timeline fits.

Working rule: WBC/neutrophils are the most relapse-sensitive CBC markers. Platelet count may also be influenced by smoking/inflammation, but Dag's platelets have been high across multiple years and smoking states, so persistent thrombocytosis still keeps its own reactive-vs-clonal pathway. Alcohol-plus-smoking periods should be treated as major personal destabilizers for gut symptoms, iron recovery, and marker interpretation, not as a dated lab-grade exposure log.

Clean-month targets

Track these as relapse-sensitive signals:

Alcohol: not a useful Lp(a) strategy

Older literature reported that moderate alcohol can reduce Lp(a) concentrations, and this effect was discussed in a BMJ review/commentary. [PMID: 9603764]

That should not be used as a reason to drink in this profile. The tradeoff is bad:

• any possible Lp(a) reduction is indirect, modest, and not the clinical target
• alcohol raises blood pressure risk and can worsen arrhythmia risk
• alcohol can worsen sleep, food choices, reflux/gastritis, gut permeability, and bloating
• diverticular bleeding history plus current occult stool-blood concern makes GI irritation more expensive
• alcohol weakens the interpretability of the 30-day experiment

Therefore: no alcohol as an Lp(a) intervention. If the goal is risk reduction, the better move is LDL/ApoB control, BP measurement/control, smoking cessation, imaging, and eventual Lp(a)-specific therapy when outcomes-proven and accessible.

Personal interpretation update after the completed 30-day abstinence period: alcohol avoidance now has stronger practical support than before. The strongest supported claim is destabilization of gut symptoms, iron recovery, and inflammatory/reactive marker patterns; it does not prove alcohol alone causes bleeding, because the alcohol periods also clustered with smoking, irregular eating/routine, and poorer recovery.

Cannabis / dry-herb vaping boundary

Dry-herb cannabis vaping is not tobacco smoking: no nicotine and much less combustion exposure than joints/spliffs. But heavy daily use has a different risk profile, mainly THC-dose, dependence/withdrawal, sleep/cognition/mental-health effects, cannabinoid hyperemesis, impaired driving, and possible cardiovascular triggering. The current owner is Daily Cannabis / Dry-Herb Vaping Risk; for the clean experiment and BP/imaging phase, daily cannabis would be a confounder rather than a useful harm-reduction tool.

Relapse interpretation rule

If smoking or alcohol happens during the experiment, log it rather than hiding it. Do not discard the whole month automatically.

Use a 72-hour interpretation window:

• mark BP/HRV/sleep/gut symptoms for the next 3 days as potentially confounded
• do not overinterpret a single high BP day, bad sleep night, or bloating flare immediately after relapse
• if relapse repeats, treat the month as a behavioral/adherence signal rather than a clean physiology experiment

Actionable summary for Dag

1. Smoking abstinence is the strongest modifiable Lp(a)-context intervention.
2. Alcohol abstinence is not about lowering Lp(a); it is about BP, sleep, gut/bleed risk, and clean data.
3. Do not use aspirin/NSAIDs to compensate for high Lp(a) risk while occult stool-blood/bleeding risk is unresolved.
4. Measure what changes: BP, resting HR/HRV, sleep, bloating, stool, CRP/WBC/neutrophils/fibrinogen/platelets, ferritin/TSAT.
5. The 30-day experiment should treat relapse as data, but repeated relapse makes marker interpretation much weaker.
6. Reconstruct the smoking-status timeline for older CBC dates before treating historical WBC values as evidence for or against smoking-related leukocytosis.
7. Treat late-2025 ferritin decline as exposure-confounded because the next-day stool blood/RBC test was negative; April 2026 remains the clearer stool-positive bleeding signal.

Evidence trace

• Research date: 2026-04-27
• Research mode: PubMed/literature review + integration with current KB constraints
• Search focus: Lp(a) stability, smoking/inflammation/fibrinogen, smoking cessation risk markers, WBC/neutrophil reversibility, alcohol and Lp(a), lifestyle with elevated Lp(a)
• Evidence anchors: PMID: 18362252, PMID: 37712231, PMID: 3565227, PMID: 15974805, PMID: 16092581, PMID: 27583199, PMID: 9603764
• KB integration anchors: very high Lp(a), no aspirin primary prevention while GI bleeding risk remains live, 30-day experiment signal quality, and historical CBC interpretation requiring smoking-status labels

Important Daily Cannabis / Dry-Herb Vaping Risk

cannabis · dry-herb-vape · thc · cardiovascular-risk · cognition · sleep · addiction

Daily Cannabis / Dry-Herb Vaping Risk

Summary

A dry-herb vape is a harm-reduction route compared with burning joints, but it does not make heavy daily cannabis benign. At 20 g/week, use averages 2.86 g/day. If flower is 15-25% THC, the raw plant contains roughly 430-714 mg THC/day before delivery losses. That is far beyond “occasional” use and lands in the guideline-defined high-risk pattern: daily/near-daily, high cumulative exposure.

Practical comparison:

Bottom line: not as bad as a pack/day cigarette habit, but bad enough that it should not be treated as a harmless substitute. For this profile, daily high-dose THC would be a risk multiplier and a data-confounder.

Why this matters in this profile

Distinct risks vs cigarettes

Cigarettes are mainly a combustion/nicotine vascular-cancer machine. Cannabis is mainly a THC-exposure and impairment/dependence problem, with cardiovascular uncertainty layered on top.

Lower-risk rule if cannabis is used anyway

• Avoid daily/near-daily use; the guideline-compatible direction is occasional use, not a nightly baseline.
• Prefer lower-THC / higher-CBD flower; avoid concentrates, dabs, vape oils, synthetic cannabinoids, and any product with unclear additives.
• Keep it tobacco-free and combustion-free; dry-herb vaporizer beats joints, spliffs, and bongs for respiratory toxicant exposure.
• Do not drive or ride in risky traffic after use; Lower-Risk Cannabis Use Guidelines advise waiting at least 6 hours after use before driving, and longer if still impaired.
• Keep use out of any measurement window meant to answer BP, sleep, inflammatory marker, GI, or exercise-performance questions.
• Treat morning nausea, cyclic vomiting, abdominal pain with hot-shower relief, escalating dose tolerance, inability to skip days, or withdrawal insomnia/anxiety as stop signals.

Action

For the current health plan: do not add daily cannabis during the 30-day experiment, final labs, BP profiling, or cardiac-imaging phase. It would make the most important open questions harder to interpret.

If cannabis becomes a deliberate experiment later, make it a separate logged exposure with a pre-set ceiling: non-daily, low-THC/high-CBD, dry-herb only, no driving, and stop if sleep, HR/BP, anxiety, appetite, GI symptoms, or exercise consistency worsens.

Evidence / context

• Dry-herb vaporizing can reduce carbon monoxide and several combustion-related toxicants compared with smoked cannabis, but long-term outcome data are limited and vaping is not risk-free. (Chaiton et al., 2022; PMCID: PMC8975973)
• AHA scientific statement: cannabis has few cardiovascular benefits and several cardiovascular concerns; route and product type matter. PMID: 32752884
• BRFSS 2016-2020 cross-sectional analysis: daily cannabis use was associated with higher adjusted odds of MI, stroke, and composite CVD outcomes, including among never-tobacco smokers. PMID: 38415581
• Cannabis withdrawal meta-analysis: pooled withdrawal prevalence 47% among regular/dependent users; daily use was associated with higher prevalence. PMID: 32271390
• Psychosis frequency meta-analysis: daily/near-daily cannabis use was associated with higher psychosis-development risk than no use in the best-fit model. PMID: 35321777
• Sleep review: evidence for cannabis as durable sleep treatment is weak; withdrawal can cause significant sleep disruption and relapse. PMID: 35459406
• Chronic cannabis smoking causes chronic-bronchitis-type respiratory symptoms; evidence for COPD/lung cancer is weaker than for tobacco, and dry-herb vaping is a separate lower-combustion route. National Academies 2017; Ribeiro & Ind 2016.
• Cigarette comparator: CDC summarizes smoking as raising coronary heart disease and stroke risk 2-4x; British Doctors 50-year follow-up found lifelong cigarette smoking caused large mortality loss, with quitting around age 50 recovering substantial life expectancy. PMID: 15213107

Research trace

• Research date: 2026-05-24
• Mode: safety/adverse-effects literature review + profile-specific clinical-decision synthesis.
• Source classes: existing KB smoking/Lp(a)/inflammation owners, National Academies/CDC/Canada lower-risk guidelines, AHA statement, PubMed/PMC reviews and observational studies.
• Integration outcome: new standalone behavior-risk owner because cannabis has a different mechanism/risk profile than tobacco/alcohol and is likely to recur as a decision question.

Important Blood Pressure Profile

blood-pressure · cardiovascular · lp(a) · home-monitoring · hypertension · risk-factor

Blood Pressure Profile Acquisition

SearchPlan

• Question type: diagnosis / monitoring / cardiovascular risk modification.
• Question: How should BP be collected and interpreted so it materially improves cardiovascular risk management in this high-Lp(a) profile?
• Dag-specific context: male 51, Lp(a) 838.6 mg/L, ApoB 66.31 mg/dL, LDL 2.04 mmol/L on atorvastatin, active/recent smoking, no BP series documented in the cloud doc, currently in a 30-day alcohol/smoking-free experiment.
• Concepts searched: home BP monitoring protocol, ambulatory BP monitoring, hypertension thresholds, ESC/AHA/ESH guidance, treatment targets, white-coat/masked hypertension.
• Target sources: 2024 ESC BP guideline, AHA home BP monitoring instructions, ESH-style home BP protocol summaries, existing KB cardiovascular topics.
• Stop condition: a practical collection protocol plus interpretation thresholds that decide whether BP becomes a treatment issue.

Why This Matters Here

Blood pressure is currently a blind spot. The cloud doc has detailed lipids, Lp(a), glucose, inflammation, stool, iron, and PSA trends, but no usable BP profile. That leaves a major ASCVD modifier unmeasured.

For this profile, BP does three jobs:

1. Risk modifier: high BP would compound Lp(a), smoking history, platelets/inflammation, and any plaque found on imaging.
2. Treatment-decider: if average BP is elevated, BP control may produce more immediate risk reduction than chasing marginal supplement changes.
3. Context for symptoms and imaging: high BP changes how aggressively to interpret CAC/CCTA/echo findings and recurrence of cardiac-type symptoms.

Can This Be Done Alone at Home?

Yes. A 7-day home BP profile is specifically meant to be self-measured outside the clinic. No hospital visit is needed before starting if the device is credible, the cuff fits, and the measurement technique is standardized. A clinic/pharmacy comparison reading is optional quality control, not a prerequisite.

Use professional help sooner only if:

• repeated resting readings are in the severe range (>=180 systolic or >=120 diastolic)
• high readings occur with chest pain, breathlessness, neurologic symptoms, severe headache, weakness, vision/speech change, fainting, or back pain
• the monitor repeatedly shows irregular heartbeat/AF alerts, especially with palpitations, dizziness, or shortness of breath
• the 7-day average is clearly high and treatment decisions are being considered

Equipment / Buying Rule

Use a validated automatic upper-arm cuff, not wrist/finger devices. Correct cuff size matters. Bring the device to a clinic/pharmacy/doctor once if possible to compare against a professional reading, but start the profile while waiting rather than delaying the whole dataset.

Minimum practical device spec:

• upper-arm cuff, not wrist/finger/smartwatch/cuffless
• exact model appears in STRIDE BP, ValidateBP, or another recognized validated-device list
• cuff circumference range includes the measured mid-upper-arm circumference
• stores readings or exports them, ideally Bluetooth/CSV
• movement/cuff-fit warning is useful
• easy enough to use repeatedly without making the protocol annoying

Phnom Penh / online buying checklist:

1. Measure mid-upper-arm circumference before ordering.
2. In Grab Mart, search UCare and other major pharmacy/home-care merchants for Omron, Microlife, A&D, Rossmax, Beurer, or another model that can be checked in STRIDE BP / ValidateBP.
3. Prefer Cambodia-listed Omron upper-arm models that also appear in validation sources. As of 2026-05-03, Omron Cambodia/Asia pages list models such as HEM-7361T, HEM-7156T, HEM-7143T1, HEM-7142T1, and HEM-7141T1; validation status is model-specific, not brand-wide.
4. Stronger choices from the current search: HEM-7361T is listed by STRIDE BP with ISO 81060-2:2018 validation published in 2025; HEM-7143T1 / M2 Intelli IT variants appear in STRIDE BP home lists as validated/equivalent. HEM-7141T1 and HEM-7142T1 were found on Omron pages but not confirmed in peer-reviewed/STRIDE evidence during this pass, so do not treat them as equal if better models are available.
5. Avoid anonymous marketplace devices whose exact model cannot be validated. The GrabMart-indexed CK-A156 upper-arm monitor is a lead only; this pass did not find it in STRIDE BP or ValidateBP, so it is a poor first choice for a profile that may drive medical decisions.
6. If the app listing is vague, message/call the pharmacy before ordering: “Please confirm exact BP monitor model number, cuff size range in cm, and whether it is upper-arm. I need a clinically validated device.”

7-Day Home BP Protocol

Use the AHA/ESH-style pattern:

If using the current experiment period, treat it as a clean-month BP baseline: no alcohol/smoking should reduce noise and make the average more interpretable.

Interpretation Thresholds

When BP Changes Cardiovascular Management

BP becomes management-changing if any of these are true:

• 7-day home average is repeatedly >=130/80 (US category) or especially >=135/85 (home-hypertension threshold)
• morning readings are consistently high even if evening readings are better
• BP is high during the same period as smoking/alcohol relapse, poor sleep, or high stress
• CAC/CCTA/echo shows plaque, LV hypertrophy, aortic valve disease, or other target-organ signal
• symptoms recur in a cardiac-like pattern

If imaging documents plaque, BP targets should be discussed more aggressively. The 2024 ESC guideline moved toward systolic 120-129 mmHg as an on-treatment target for most adults who tolerate BP medication, but this is a clinician target, not a self-treatment instruction.

ABPM vs Home BP

What to Log in Tracker

Add a simple BP entry when measured:

BP 126/78 HR 62, morning, before coffee, rested 5 min, no nicotine/alcohol, cuff left arm

If readings are high, log the context rather than repeating obsessively:

• coffee/nicotine/exercise within 30 minutes
• sleep quality
• stress
• illness/pain
• alcohol/smoking relapse
• time since meal

Key Takeaways for This Profile

1. BP is the biggest missing routine cardiovascular variable in the current KB.
2. You can start the 7-day profile alone at home; the non-negotiable is a validated upper-arm cuff with the right cuff size, not a hospital visit first.
3. Home average >=135/85 is clearly actionable; >=130/80 is already relevant under AHA categories, especially with Lp(a) 838.6 mg/L.
4. For Phnom Penh online ordering, use Grab Mart/UCare-style pharmacy sourcing only if the listing exposes the exact model and cuff size; anonymous unvalidated devices should not drive medical decisions.
5. If BP is elevated and imaging later shows plaque, BP treatment intensity becomes a core cardiovascular decision, not a side issue.
6. During the 30-day clean experiment, BP readings are unusually valuable because alcohol/smoking confounding is reduced.

Research Trace

• Research dates: 2026-04-27 and focused sourcing update 2026-05-03.
• Research mode: clinical decision synthesis plus Phnom Penh local-access/product verification.
• Sources searched: live cloud doc, existing KB cardiovascular/access topics, 2024 ESC elevated BP/hypertension guidance, AHA home BP monitoring instructions, ESH-style home monitoring protocol summaries, PubMed/systematic-review pass, STRIDE BP / ValidateBP device-validation resources, Omron Cambodia/Asia product pages, UCare/GrabMart web-indexed Phnom Penh listings.
• Evidence anchors: 2024 ESC BP guideline (PMID: 39210715); self-measured BP systematic review (PMID: 23922064); STRIDE BP home-device list generated 2026-05-03; STRIDE BP Omron HEM-7361T page; Omron Cambodia Connect product list; AHA home BP technique guidance.
• Unresolved gap: actual home BP average and exact live Grab Mart stock by neighborhood/store.

Important Sleep Apnea + Nocturnal BP

sleep-apnea · nocturnal-hypoxia · blood-pressure · apple-watch · hsat · cardiovascular · lpa

Sleep Apnea + Nocturnal Hypoxia + Autonomic BP Phenotype

Summary

Classification: INTEGRATE. The active queue item needs a compact standalone router because it connects home BP, Apple Watch sleep signals, local sleep-test logistics, and the high-Lp(a) cardiovascular risk plan.

Current call: do not buy or book a sleep test blindly. Use trigger-based screening first. In this profile the already-known STOP-BANG points are age >50 and male sex; BMI is about 24, and the cloud doc does not document loud habitual snoring, witnessed apneas, daytime sleepiness, or confirmed hypertension. That is not enough to diagnose or strongly suspect OSA.

Current signal

• Male, 51, BMI about 24.1 from 78 kg and 180 cm.
• Longstanding insomnia history improved in Southeast Asia; current cloud doc says sleep pattern is normal when cannabis is available.
• No documented snoring, witnessed apneas, choking/gasping, excessive daytime sleepiness, or morning headaches in the cloud doc.
• No usable home BP profile yet; BP remains the major missing cardiovascular variable.
• Apple Health already has sleep/HRV/RHR/respiratory-rate/SpO2 coverage from late 2025 onward, but isolated SpO2 lows or HRV nights should not be overread.
• Very high Lp(a) means any real OSA/hypertension combination matters as a risk amplifier, but Lp(a) alone is not an OSA diagnosis.

Decision pathway

Cheap screening path

1. Question check: ask or observe: snoring >3 nights/week, snoring louder than talking, witnessed pauses, gasping/choking, dry mouth/morning headache, nocturia, unrefreshing sleep, daytime sleepiness, dozing, concentration issues.
2. BP first: complete the 7-day upper-arm home BP profile. Morning hypertension or high average BP is the most actionable bridge into OSA screening.
3. Watch data second: keep Sleep Focus/manual sleep capture consistent. Treat breathing-disturbance notifications, repeated SpO2 dips, respiratory-rate jumps, high resting HR, and low HRV as prompts to verify, not proof.
4. If trigger-positive: Royal Phnom Penh Hospital is the Phnom Penh-first route because its public sleep article says it offers sleep consultation, in-lab polysomnography, and home sleep apnea testing. Ask: “Do you offer HSAT for suspected obstructive sleep apnea, what device type, AHI/ODI output, oxygen nadir/time-below-90%, and physician interpretation?”
5. If local route fails: Bangkok Hospital has a WatchPAT home-test pathway; this is a fallback, not the default.
6. Treatment sequence: CPAP is the standard for confirmed clinically significant OSA; oral appliances are usually a clinician/dentist-guided option for primary snoring or mild-moderate OSA / CPAP intolerance, not a substitute for diagnosis.

What a positive result would change

• BP handling: OSA would make morning/nocturnal BP control more important and would strengthen the case for ABPM if home readings are borderline or discordant.
• Cardiovascular priority: with very high Lp(a), confirmed OSA is another risk amplifier to clean up, similar to smoking/BP rather than a replacement for lipid/plaque/valve work.
• Inflammation interpretation: if OSA is confirmed and treated, resting HR/HRV, morning BP, sleepiness, and possibly CRP/IL-6/TNF-alpha can be tracked, but inflammatory markers are secondary.
• Imaging remains separate: OSA treatment does not replace CAC/CCTA/echo decisions for Lp(a), aortic-valve, or plaque assessment.
• Expected effect size: CPAP tends to lower BP modestly in general OSA/hypertension and more clearly in resistant hypertension; large cardiovascular event reduction is not guaranteed, especially if adherence is poor or symptoms are minimal.

Evidence / context

AASM diagnostic guidance is the anchor: questionnaires and prediction tools should not diagnose OSA without objective sleep testing; HSAT is appropriate for uncomplicated adults with signs/symptoms suggesting moderate-severe OSA, while PSG is preferred when comorbidities or inconclusive HSAT results make home testing unreliable. USPSTF gives an insufficient-evidence statement for screening asymptomatic adults, so this branch should be trigger-based rather than universal screening.

The cardiovascular rationale is real but should not be inflated. The AHA statement describes OSA as intermittent hypoxemia, autonomic fluctuation, and sleep fragmentation, with high prevalence in hypertension and cardiovascular disease. STOP-BANG is useful for triage because sensitivity is high, but specificity is modest; it is a “who should be tested?” tool, not a diagnosis. CPAP meta-analyses show small average BP reductions and larger reductions in resistant hypertension, while cardiovascular outcome trials such as SAVE did not show broad event prevention from CPAP on top of usual care. That makes symptom/BP/autonomic improvement the near-term target.

Local logistics are better than expected: Royal Phnom Penh Hospital has public sleep-apnea pages describing a sleep lab, sleep specialist consultation, in-lab polysomnography, and HSAT. Roomchang Dental Hospital advertises a home-monitoring plus oral-appliance pathway; treat that as a dental-treatment route after diagnostic clarity, not the first medical workup for cardiovascular-risk interpretation.

References

• AASM diagnostic testing guideline: PMID: 28162150; AASM HSAT position statement: PMID: 28942762.
• USPSTF adult OSA screening statement: PMID: 36378202.
• AHA OSA and cardiovascular disease statement: PMID: 34148375.
• STOP-BANG cardiovascular-risk-factor meta-analysis: PMID: 33664122; broader questionnaire meta-analysis: PMID: 27919588.
• CPAP BP evidence: resistant-hypertension meta-analysis PMID: 38460066; OSA+hypertension RCT meta-analysis PMID: 25582849. Cardiovascular outcomes: SAVE trial PMID: 27571048; adherence-focused IPD meta-analysis PMID: 37787793.
• CPAP inflammatory-marker evidence: RCT meta-analysis PMID: 40346316; older biomarker meta-analysis PMID: 29682699.
• Local sources checked 2026-05-03: Royal Phnom Penh Hospital sleep-test/sleep-apnea pages; Roomchang Dental Hospital snoring/OSA page; Bangkok Hospital WatchPAT home-test page.

Important Longitudinal Cohort Risk Translation

cohort-studies · life-expectancy · lipoprotein-a · smoking · blood-pressure · inflammation · cardiovascular-risk

Longitudinal Cohort Risk Translation

Summary

Population cohorts cannot calculate an individual expiry date. They are still valuable because they show which measurements keep predicting hard outcomes after years or decades.

For this profile, the strongest matches are:

1. Lp(a) cohorts: Copenhagen, pooled US cohorts, MESA/Dallas, EPIC-Norfolk, Reykjavik/ERFC.
2. Life-course risk cohorts: Framingham for BP/lifetime CVD; British Doctors and Framingham for smoking.
3. Diverticular disease cohorts: Health Professionals Follow-up Study, Nurses' Health Study/NHS II, EPIC-Oxford, Million Women Study, UK Biobank, Swedish cohorts, and Danish registries.
4. Inflammation/hemostasis cohorts: ERFC CRP and Fibrinogen Studies Collaboration.
5. Large treasure-trove biobanks: UK Biobank, All of Us, China Kadoorie, HUNT, Rotterdam, Malmö, WHI, Adventist Health, ARIC, CARDIA, MESA, REGARDS.

The practical translation is not “panic because one marker is high.” It is: measure the modifiable high-impact variables, keep ApoB/LDL suppressed, stop smoking, get BP out of the blind spot, use imaging to learn whether very high Lp(a) has already produced coronary plaque or valve disease, and treat diverticular evidence as risk-hygiene rather than a precise rebleeding forecast.

Major cohort atlas

This is intentionally broader than the direct Lp(a) question. Some cohorts answer Dag-specific questions directly; others are simply reusable data mines worth knowing about.

Lp(a) and life expectancy / mortality

The most directly relevant mortality paper is Copenhagen:

Diverticular disease cohort signals

This was underweighted in the first pass. The main diverticular evidence does not usually measure Lp(a), but it is still directly relevant because it tracks diet, activity, smoking, obesity, bleeding/diverticulitis outcomes, and hospitalization.

Practical diverticular translation: cohorts support fibre-rich diet, activity, weight stability, smoking abstinence, and not fearing nuts/seeds by default. They do not precisely predict personal rebleeding risk after a known diverticular bleed; that still depends on clinical history, stool blood, iron/Hb trends, medication exposures, and colonoscopy quality.

What matches Dag most closely

Practical conclusions

1. The direct Lp(a)-and-survival match exists, but it is not a personal lifespan forecast. Copenhagen shows higher cardiovascular and all-cause mortality at very high Lp(a), but the individual decision remains risk-factor control plus disease-burden imaging.
2. Smoking abstinence has the clearest life-expectancy signal. The British Doctors cohort is blunt: continuing smoking cost about 10 years; quitting at around 50 recovered about 6 years versus continuing.
3. Blood pressure is the biggest current missing cohort variable. Framingham found 50-year-old normotensive men lived about 5.1 years longer overall and 7.2 years longer free of CVD than hypertensive men.
4. CAC/echo/CCTA are how cohort risk becomes personal risk. MESA says Lp(a) and CAC are independently useful; CAC=0 is reassuring for coronary events, while CAC >=100 plus high Lp(a) is a much more aggressive-prevention signal. Echo remains separate because Lp(a) also tracks aortic-valve risk.
5. Diverticular cohorts are relevant even without Lp(a). HPFS/NHS/EPIC/Million Women/UK Biobank/Swedish data support fibre-rich diet, physical activity, smoking abstinence, weight stability, and not avoiding nuts/seeds by default; they do not predict personal rebleeding precisely.
6. Inflammation markers should be used for context, not fear arithmetic. CRP/fibrinogen/IL-6 cohorts support risk relevance, but Lp(a) itself does not appear to causally create CRP-driven low-grade inflammation.

Action

• Complete the validated home BP profile during the clean experiment window.
• Keep smoking abstinence as the highest-value behavioral intervention.
• Keep ApoB/LDL low; discuss intensification only in the context of imaging, targets, cost/access, and clinician input.
• Prioritize baseline echo plus CAC/CCTA pathway when feasible.
• Repeat CBC/differential, platelets, CRP/ESR, fibrinogen, ferritin/TSAT after the experiment to see whether the inflammatory-thrombotic context improves.
• For diverticular disease: use cohort evidence as long-term hygiene support — fibre-rich vegetarian pattern as tolerated, steady activity, smoking abstinence, weight stability, no routine nut/seed avoidance, and bleeding-safe medication choices.
• Do not treat aspirin as solved by Lp(a) cohort studies; the GI bleeding branch still dominates aspirin safety.

Research trace

• Research date: 2026-05-03.
• Research mode: enhanced retrieval literature review + clinical decision synthesis.
• Sources searched: existing cloud doc and KB; PubMed/E-utilities; PubMed page extraction; web orientation for Copenhagen, ERFC, EPIC-Norfolk/Oxford, UK Biobank/MESA, Framingham, British Doctors, HPFS, Nurses' Health/NHS II, Million Women, Swedish and Danish diverticular cohorts, CRP/fibrinogen collaborations.
• Counter-checks: looked for total-mortality/life-expectancy endpoints, not just ASCVD; checked whether Lp(a) causes low-grade CRP inflammation; separated cohorts with direct Lp(a) data from adjacent risk-factor cohorts; added major cohort/data-trove coverage even when no Lp(a) variable exists.
• Evidence anchors: PMID: 30608559, 18086931, 19622820, 38631771, 35210030, 23065826, 18362252, 15983235, 35430874, 15213107, 8275219, 3565227, 15974805, 20031199, 16219884, 25938632, 41217319, 36036785, 7942584, 9521633, 7883230, 7606311, 18728264, 19367267, 21771850, 24385599, 31397679, 28065788, 31712072, 39307185, 40324196, 22008890, 26734968, 40592564.

Important Cardiac Imaging & Valve Plan

cardiovascular · imaging · cac · ccta · ldncp · lp(a) · echo · aortic-stenosis · ct-screening · phnom-penh

Cardiac Imaging & Valve Plan

This is the single current owner for CAC/CCTA/AI-QCT, CT screening boundaries, echo, and aortic-valve surveillance.

Current conclusion

Very high Lp(a) creates two different imaging questions:

1. Coronary plaque track: CAC and CCTA ask whether Lp(a), smoking, BP, and ApoB history have already produced coronary plaque, stenosis, or high-risk plaque features.
2. Valve / LV / vascular-aging track: transthoracic echo asks whether Lp(a) has produced aortic sclerosis/stenosis, valve gradients, valve area, LV hypertrophy/function, or aortic-root/ascending-aorta findings.

Old RPPH papers found in June 2026 add one important baseline: a 2024-01-22 right-leg arterial Doppler already showed mild peripheral atherosclerosis/PAD — mixed plaque in the right common femoral artery with 24-31% stenosis, plus thin calcified/soft plaque in SFA/popliteal artery without significant stenosis. That is not coronary imaging and does not answer the aortic-valve question, but it means the cardiovascular workup is no longer starting from “no documented plaque anywhere.” Archive ID: rpph-2024-01-22-cardiology-orthopedic-papers.

CAC is the simplest coronary anchor if asymptomatic and logistics matter. But CAC measures calcified plaque only. In high Lp(a), the blind spot is low-density/non-calcified plaque detectable by CCTA/quantitative plaque analysis. Echo is not optional “extra CT detail”; it answers a separate Lp(a)-valve question that CAC/CCTA do not answer.

The early-April 2025 severe epigastric/upper-abdominal/chest-ish pain with sweating/dizziness/left-arm or hand symptoms is a symptom override: if that pattern recurs, do same-day ECG + high-sensitivity troponin / possible-ACS rule-out first. That is not screening.

What changes the decision

What to do now

What not to do

Evidence and owner links

• Prevention owner: ASCVD / Lp(a) Prevention Master.
• BP owner: Blood Pressure Profile, Sleep Apnea + Nocturnal BP.
• Local logistics owner: Phnom Penh Medical Access.
• Recurrence/acute symptom owner: Recurrence Action Plan.
• Bleeding/antiplatelet safety owner: GI Bleeding / Diverticular / Stool Blood, Medication List + Hard Avoids.

Preserved evidence anchors include Lp(a)/CCTA non-calcified or high-risk plaque evidence (PMID: 36503252; PMID: 38692827; PMID: 42054506; PMID: 41908166), statin plaque-composition effects (PMID: 29909109; PMID: 32160786), AI-QCT/quantitative CCTA evidence (PMID: 38752951; PMCID: PMC11683154), CAC/Lp(a) risk refinement and CAC=0 limitations (PMID: 38300625; PMID: 39012945), ACC/AHA CAC guidance (PMID: 30423393; PMID: 30879355), ESC chronic coronary syndrome/CCTA guidance (PMID: 39210710), Lp(a)-aortic-valve evidence and progression (PMID: 23388002; PMID: 24161338; PMID: 39018080; PMID: 26361154; PMID: 31047003), ESC/EACTS valve surveillance guidance (PMID: 34453165), BP variability/arterial-stiffness context (PMID: 27906836; PMCID: PMC11901005), and ACR/FDA/USPSTF cautions against broad CT screening.

Important Medication List + Hard Avoids

medications · supplements · aspirin · nsaids · statin · diverticular-bleeding · lp(a) · safety

Canonical Medication List + Hard Avoid List

Source-of-truth limitation

This list is only as good as the cloud-doc medication/supplement section. Update it whenever a prescription, supplement, OTC drug, eye drop, topical product, or pain patch becomes routine.

Latest reconciliation status: partial. The original medication list is dated 2025-10-11; a 2026-05-04 cloud-doc update confirms atorvastatin 20 mg, cortisone cream for eczema flare-ups, and no aspirin. Old RPPH papers from 2024-01-22 show a historical post-Doppler prescription/recommendation of aspirin 81 mg, Lipitor/atorvastatin 40 mg, and omeprazole 20 mg on the billing sheet. Eye-drop identity, sildenafil timing/frequency, and the exact current supplement stack remain unverified.

Dated current-known list

Safety-reference audit

Historical exposure reference — OTC topical mupirocin

Private archive identifier: topical-mupirocin-prebleed-2025-08.

Verified from the product photo and cross-check sources:

Plausibility review completed 2026-05-07:

Evidence anchors: FDA Bactroban/mupirocin ointment label; DailyMed mupirocin ointment 2%; UK SmPC for mupirocin 20 mg/g ointment; StatPearls/NCBI Bookshelf 2024; PubMed searches on 2026-05-07 for mupirocin + hematochezia/GI bleeding/CDAD/systemic absorption/genital-mucosal terms; openFDA FAERS spot-check for bleeding/CDAD terms.

Operational rules

1. Jan 2024 mild right-leg PAD/peripheral plaque means the aspirin question is no longer pure “risk-factor-only primary prevention,” but it is still not a self-directed medication because prior diverticular bleeding/stool-blood uncertainty remains a major counterweight.
2. Obstructive CAD, MI, stroke, stent, progressive/symptomatic PAD, or cardiologist-defined chronic coronary disease → antiplatelet decision becomes clinician-led, with GI bleeding history disclosed.
3. For pain/fever, paracetamol/acetaminophen is the reflex OTC choice; avoid ibuprofen/naproxen/diclofenac and avoid combination pain/cold products that sneak in NSAIDs or duplicate APAP.
4. If chest/epigastric pain recurs and emergency care is needed, disclose sildenafil dose, last use time, and any dizziness/syncope so nitrates are not given blindly.
5. Keep the supplement stack subordinate to the safety rules: conservative omega-3 only, turmeric/curcumin stopped, oral iron only as a monitored repletion bridge, B12 reasonable if indicated, and probiotics symptom-targeted only.

What needs clarification at the next reconciliation

Current conclusion

This profile needs a conservative medication safety posture: continue lipid lowering, avoid aspirin/NSAIDs unless a clinician has a strong documented indication, disclose sildenafil in emergency chest-pain contexts, identify the eye drops, keep topical steroid use intermittent and site-aware, and prevent supplements from accidentally increasing bleeding risk, liver-risk noise, neuropathy risk, or lab-confounding.

Reference anchors

• Aspirin / primary prevention: ACC/AHA 2019 primary-prevention guideline (PMID: 30879355); USPSTF bleeding evidence review (PMID: 27064261).
• Lower-GI/diverticular bleeding medication safety: ACG lower-GI bleeding guidance summary and 2023 update (PMID: 36735555).
• Acetaminophen: DailyMed APAP 500 mg label; alcohol/therapeutic-dose context remains cautionary rather than a reason to exceed package limits (PMID: 11776481, PMID: 3511825).
• Sildenafil: DailyMed sildenafil label, nitrate/riociguat contraindication and hypotension warning.
• Eye drops: DailyMed timolol ophthalmic label; systemic ophthalmic beta-blocker evidence (PMID: 17366003, PMID: 7906296).
• Topical corticosteroids: NHS hydrocortisone guidance; topical corticosteroid adverse-effect and use reviews (PMID: 16384751, PMID: 33719380).
• Supplement safety: omega-3 bleeding meta-analysis (PMID: 38742535); NCCIH turmeric page and LiverTox turmeric update; AGA iron-deficiency update (PMID: 38864796); vitamin B6 upper-limit review (PMID: 37207271).

Research trail

• Research date: 2026-05-08.
• Research mode: clinical decision synthesis / safety-reference audit.
• Sources checked: fresh cloud doc, medication/supplement KB owners, PubMed, ACC/AHA, ACG, DailyMed, NCCIH/LiverTox, NIH ODS, NHS.
• Integration decision: INTEGRATE — replaced vague medication/supplement safety prose with a dated current-known list, a compact safety-reference audit, and sharper unresolved-product gaps; no new standalone drug topic needed.

Urgent Thrombocytosis Workup Pathway

platelets · thrombocytosis · lp(a) · thrombosis · reactive · iron-deficiency · JAK2 · essential-thrombocythemia · fibrinogen · CHIP · clonal-hematopoiesis

Thrombocytosis Workup Pathway

Summary

This page should be read as a platelet pathway. Lp(a), smoking, fibrinogen, inflammation, occult blood, and CHIP literature modify risk context, but they do not replace the core question:

Are platelets persistently elevated because of a reactive driver, or because of a clonal/myeloproliferative process?

Reactive thrombocytosis remains plausible, but not a free pass. Platelets have repeatedly been high over years: 476 (2021-07) -> 511 (2022-10) -> 409 (2024-03) -> 520 (2025-08) -> 415 (2025-10) -> 439 (2025-12) -> 494 (2026-04) -> 452 (2026-05-12) -> 444 (2026-05-27). The exposure-cleanup improvement supports a reactive component; persistence near the 450 threshold and above Biomed's reference range is why the pathway still matters.

CHIP is the useful extra lens from this queue item: acquired blood-cell clones can amplify cardiovascular risk and inflammation, but CHIP is usually a sequencing finding, not a diagnosis made from platelets alone. In this profile it should sharpen prevention and hematology framing if found; it should not become a broad screening shortcut before repeat CBC/differential, smear, reactive-cause cleanup, and focused MPN testing have done their job.

“Urgent” here means high-priority KB tracking, not emergency care unless the red flags listed in Whole-Profile Seriousness Triage appear.

Current signal

Decision pathway

Recommended sequence

1. Repeat CBC with differential — confirm platelet persistence and characterize WBC pattern.
2. Peripheral smear if platelets remain >=450, WBC remains high, or the differential is abnormal.
3. Iron/bleeding branch — ferritin, iron, TIBC/transferrin, TSAT, Hb/MCV/RDW, stool-blood follow-up.
4. Inflammation/secondary branch — CRP/ESR, infection symptoms, smoking status, eczema/allergic activity, recent bleeding, medications, malignancy/alarm symptoms, surgery/splenectomy history.
5. JAK2 V617F if thrombocytosis persists >=450 after reactive causes are corrected/less convincing, or if uncertainty reduction is worth the cost now.
6. CALR/MPL if JAK2 is negative and suspicion persists.
7. BCR-ABL1 / CML branch if smear/differential shows basophilia, left shift, unexplained leukocytosis, splenomegaly, or other CML-like features. Biomed's public tariff lists BCR-ABL/CML RT-PCR ($125), but not JAK2/CALR/MPL.
8. Broader myeloid/CHIP NGS only as a hematology-level next step: unexplained persistent counts, abnormal smear, negative focused drivers with ongoing concern, or incidental sequencing result that needs interpretation.
9. Hematology for mutation-positive results, concerning smear/differential, rising counts, splenomegaly/constitutional symptoms, or unexplained persistent thrombocytosis.

Risk modifiers: keep qualitative

Do not model this as “Lp(a) x platelets x smoking = N-fold risk.” That overstates what the evidence can support.

Aspirin and statin boundary

• Aspirin: avoid for primary prevention in the current state. GI bleeding/occult blood risk outweighs speculative platelet/Lp(a)/CHIP benefit. Even CHIP reviews caution against routine aspirin without an ischemic-event indication; a JAK2-CHIP signal would be a specialist discussion, not a self-start.
• Statin: atorvastatin remains for LDL/ApoB and plaque-risk management. Any platelet anti-inflammatory effect is secondary and should not be expected to normalize platelet count.

Current medication/supplement safety details live in Medication List + Hard Avoids; antiplatelet/aspirin tradeoffs live in ASCVD / Lp(a) Prevention Master.

Evidence / context

• Persistent thrombocytosis is commonly handled around the >=450 x 10^9/L threshold.
• Reactive causes must be excluded before diagnosing essential thrombocythemia.
• Iron-restricted states and blood loss are established reactive causes of thrombocytosis. PMID: 19804449, PMID: 28466962.
• Formal ET diagnosis requires persistent thrombocytosis plus exclusion of reactive causes and other myeloid neoplasms; classic driver mutations JAK2/CALR/MPL are present in most ET cases. PMID: 38269572.
• A 2024 thrombocytosis cohort found that molecular testing yield was mostly classic drivers: 52.4% overall yield, with 92.1% of positives in JAK2/CALR/MPL. Secondary predictors included active malignancy, chronic inflammatory disease, splenectomy, and iron deficiency; ET predictors included arterial thrombosis and higher Hb/MCV/RDW/MPV. PMID: 38375212.
• CHIP is generally defined as a leukemia-driver mutation in blood at VAF >=2% without overt hematologic neoplasm/cytopenia/dysplasia; common genes include DNMT3A, TET2, ASXL1, and JAK2. It is age-related and often has normal counts, so it is not diagnosed by platelet count alone. PMID: 31345432, PMID: 36355225.
• CHIP is associated with roughly doubled ASCVD risk in reviews and a 1.9-fold coronary-heart-disease signal in prospective nested case-control data; TET2/JAK2 appear more actionable biologically than generic CHIP labels. PMID: 28636844, PMID: 31345432.
• Current expert reviews do not support routine CHIP screening in unselected cardiovascular patients. If CHIP is found, the practical response is stringent conventional prevention and specialist interpretation, not aspirin/anti-inflammatory self-treatment. PMID: 31345432, PMID: 40841104.
• JAK2 V617F clonal hematopoiesis has a stronger thrombotic/platelet-activation signal than many CHIP genes, but this strengthens the case for hematology/cardiology involvement rather than bypassing the stepwise workup. PMID: 38142422.
• Triple-negative unexplained persistent thrombocytosis can still require hematology-level workup rather than reassurance. PMID: 41344872.
• Statins may have platelet-activation effects in some studies, but that is not a substitute for thrombocytosis workup. PMID: 10882439.
• Biomed public tariff check on 2026-05-03 found CBC/Hemogram ($2.50) and BCR-ABL/CML RT-PCR ($125), but no listed JAK2/CALR/MPL or broad CHIP/myeloid NGS assay.

Action

1. Short-interval repeat: CBC with differential, ferritin/iron/TIBC/TSAT, CRP/ESR, stool-blood follow-up.
2. Add smear if platelets remain >=450 or WBC remains high.
3. If reactive branch strengthens, fix/monitor that branch and watch platelet response.
4. If platelets remain >=450 after bleeding/iron/inflammation stabilize, order JAK2 V617F, then CALR/MPL if needed; if local access is unclear, do this through hematology rather than improvising broad sequencing.
5. If WBC differential or smear points myeloid, escalate beyond ET-only thinking and include CML/BCR-ABL1 consideration.
6. If CHIP is found incidentally or via hematology NGS, treat it as an added CVD/thrombosis risk modifier: stricter smoking/BP/ApoB/plaque-imaging management, but no self-start aspirin or CHIP-directed drug while GI blood risk is unresolved.

Important Inflammatory-Thrombotic Axis

inflammation · thrombosis · ESR · fibrinogen · platelets · CRP · calprotectin · IgE · IL-6 · systemic-inflammation · diverticular · eczema

Inflammatory-Thrombotic Axis

Profile Summary

Multiple markers have formed an inflammation-thrombotic cluster, but the April-to-May 2026 sequence changed the weighting:
- Platelets: 409-520 historically; 494 (2026-04-19) -> 452 (2026-05-12, ref max 348) -> 444 (2026-05-27) — improved to just below 450 but still above Biomed's reference range
- WBC: 13.1 (2026-04-19) -> 8.2 (2026-05-12) -> 7.7 (2026-05-27); WBC normalized through the clean-month follow-up
- Fibrinogen: 3.5 g/L (late 2025) -> 3.7 g/L (2026-04-26) -> 3.9 g/L (2026-05-27) — high-normal and not clearly improved
- ESR: 20 mm/h (2026-04 and 2026-05-27) — still at the top of normal / borderline
- CRP: 38.52 during a 2024 acute inflammatory episode, then ~2.2-2.9 in 2025-2026; 2.52 on 2026-05-27 — normal but still above the old near-zero baseline
- Calprotectin: 141 -> 87.7 -> 13.3 ug/g — now normalized
- IgA: 634.7 -> 546.6 mg/dL — improved but still above range; true protein electrophoresis showed no obvious narrow M-spike
- Total IgE: 375 -> 144 kU/L historically — still relevant for allergic/eczema tone
- Lp(a): 838 mg/L — prothrombotic
- Smoking history, diverticular disease, chronic eczema

1. Outcome meaning — what persistent systemic inflammation can damage

The strongest evidence is cardiovascular, not vague “aging damage.” In large cohorts, higher CRP tracks with coronary disease, ischemic stroke, vascular mortality, non-vascular mortality, and all-cause mortality, but much of the signal overlaps with smoking, adiposity, BP, lipids, infection, and other inflammatory markers. Anti-inflammatory treatment trials in established ASCVD support a causal vascular component, but they do not mean that every mildly raised CRP in primary prevention needs an anti-inflammatory drug.

For this profile the practical interpretation is:

Current severity call: CRP 2.52 mg/L, ESR 20, fibrinogen 3.9, persistent/borderline platelets, and normalized WBC are enough to call this an inflammatory-thrombotic context, but much less acute-looking than the April CBC. They are not enough to prove severe systemic inflammatory disease. The platelet/fibrinogen persistence is the part that most needs objective repeat and smear/source logic; WBC normalization after abstinence strengthens a reactive/exposure component unless it recurs.

Persistence should be judged with the follow-up set: CBC + differential, platelets, CRP/hsCRP, ESR, fibrinogen, ferritin/iron/TIBC/TSAT, and stool-blood follow-up. If CRP falls below ~1-2, WBC stays normal, platelets trend below 450, and stool/iron remain stable, the “damage/aging” concern should downgrade. If WBC/platelets/CRP/fibrinogen persist despite smoking/alcohol abstinence, quiet calprotectin, and stable iron/stool results, the branch deserves more serious clinician-led source hunting.

Smoking-status and alcohol/smoking exposure labeling are now part of the CBC interpretation. Current smoking can raise WBC and absolute neutrophils and is reversible after cessation, so the April 2026 WBC/ANC spike should be interpreted against the clean-month improvement. But historical values include smoke-free spikes (for example 2025-11-07) and exposure-confounded normal values (2025-12-22 now likely heavy alcohol/cigarette use), while 2018-2024 smoking status is not yet back-labeled. Do not use the older WBC series as a clean smoking correlation until those periods are reconstructed.

2. Intervention hierarchy — reducing the signal without chasing CRP

Classification: INTEGRATE. The active queue item is resolved here rather than as a new topic: the useful output is a ranked action table attached to the inflammatory-thrombotic anchor.

Operational rule: if the clean-month repeat shows CRP <1-2, WBC normal, platelets trending <450, fibrinogen stable/lower, and stool-blood/iron stable, the systemic-inflammation branch should downgrade. If the same abnormalities persist despite zero smoking/alcohol and quiet gut markers, source-hunting moves up: smear/CBC pathway, oral/skin/infection check, sleep/BP branch, and GI-source branch by trigger.

Dental/periodontal source check

Classification: INTEGRATE. The queue item resolves as a checklist inside this owner topic, not as a new standalone page. The cloud document has no recorded gum/dental symptom history, so the current status is unknown rather than reassuring.

Do not overstate this. Periodontitis is associated with CVD and systemic inflammation, and non-surgical periodontal therapy can improve IL-6/SBP and probably CRP when disease exists. But event-prevention RCT evidence is very low-certainty, so the reason to act is: preserve teeth, remove a chronic infection/inflammatory source, and reduce risk friction in a very high-Lp(a) profile — not because dental scaling is a substitute for BP/ApoB/imaging/smoking control.

3. The Inflammatory-Thrombotic Cluster — How Markers Interact

The Pathophysiology

Chronic inflammation drives thrombosis through multiple convergent pathways:

Inflammation -> Thrombosis (Immunothrombosis)
1. Inflammatory cytokines (IL-6, TNF-alpha) increase hepatic production of fibrinogen — an acute phase reactant AND the primary clotting substrate. Higher fibrinogen = more clot-forming material = hypercoagulable state.
2. IL-6 stimulates thrombopoietin (TPO) — increasing platelet production. High platelets = more clotting potential.
3. Inflammation induces tissue factor expression on monocytes and endothelial cells — initiating the extrinsic coagulation cascade.
4. Inflammation suppresses natural anticoagulants — protein C, antithrombin, and TFPI are downregulated.
5. Inflammation impairs fibrinolysis — increases PAI-1 (plasminogen activator inhibitor), preventing clot breakdown. Lp(a) adds to this by competing with plasminogen.

In Dag's case: the old model leaned heavily on diverticular inflammation (calprotectin 87-141) plus eczema/allergic activity. After the April 2026 normalization of calprotectin, the cluster looks more split: systemic inflammatory tone may still exist, but the gut inflammatory component is no longer the dominant explanation.

4. ESR Elevated + CRP Normal — What Does This Pattern Mean?

ESR >20 with CRP <5 is a distinctive pattern:

CRP vs ESR — Different Information

• CRP responds to acute inflammation (IL-6-driven). Rises in 6-8 hours, falls in 2-3 days when inflammation resolves. Dag had one clearly acute spike at 38.52 in 2024-03; the current pattern is much lower at 2.36-2.91 (normal, but up from the older <1 baseline).
• ESR responds more slowly and is influenced by additional factors: fibrinogen level, immunoglobulin levels, anemia. Elevated ESR with normal CRP often suggests:
  • Chronic, low-grade inflammation (not acute)
  • Elevated fibrinogen (3.5 g/L) directly increases ESR (fibrinogen causes RBC stacks = faster sedimentation)
  • Elevated immunoglobulins: IgA is elevated; IgG and IgM are now normal, so this looks more like isolated IgA than broad hypergammaglobulinemia
  • Anemia / low red-cell mass (Hb 13.0/RBC 4.3 in 2025-10, Hb 13.1 in 2025-12) can increase ESR

For Dag

The ESR/CRP pattern still looks most consistent with chronic low-grade inflammation or inflammatory tone, not acute flare. But it now aligns less with active gut mucosal inflammation and more with a mix of: eczema/allergic activity, possible immunoglobulin-driven ESR contribution (IgA), smoking, and whatever is sustaining the platelet/WBC picture.

The current CRP rise from <1 to ~2.9 is NOT clinically alarming in isolation, especially compared with the resolved 38.52 acute spike in 2024-03, but it does confirm that the old near-zero baseline is gone. The key shift is that positive stool blood and normalized calprotectin mean bleeding and inflammation should no longer be treated as the same process.

5. Fibrinogen at 3.7 — Context Marker, Not a Diagnosis

Evidence

• Fibrinogen is both an inflammatory and hemostatic marker associated with cardiovascular risk in population studies.
• Dag's fibrinogen moved from 3.5 g/L in late 2025 to 3.7 g/L on 2026-04-26. Both values are high-normal, not a standalone diagnosis.
• Its best use here is as a repeatable context marker for inflammatory/thrombotic tone during the clean-month experiment, not as a precise personal risk multiplier.

For Dag

Fibrinogen belongs in the same risk context as:
- Lp(a) 838 mg/L — major ASCVD / aortic-valve risk enhancer; fibrinolysis effects are mechanistic and less clinically settled
- platelets 409-520 historically and 494 in April 2026 — persistent thrombocytosis needing its own workup path
- smoking history — endothelial damage, platelet activation, inflammation, and fibrinogen/coagulation effects

The useful conclusion is qualitative: the cluster makes smoking cessation, BP measurement, plaque/valve imaging, and platelet/WBC follow-up more important. It should not be described as a simple “triad” or converted into an arithmetic clot-risk estimate.

6. Does This Create a Measurable Hypercoagulable State?

The evidence supports a prothrombotic context, but not a clean screening test

The combination of high-normal fibrinogen, thrombocytosis, very high Lp(a), and smoking history is biologically coherent. It does not create one validated blood test or calculator that can quantify Dag's personal clot risk.

Would D-dimer be useful?

Usually not as a screening shortcut.
- D-dimer measures fibrin degradation products — it rises when clot formation and breakdown are active.
- In a prothrombotic risk state without active clot turnover, D-dimer may be normal.
- Elevated D-dimer without symptoms is non-specific and can reflect inflammation, age, liver disease, infection, recent bleeding, or current occult-blood uncertainty.
- If acute symptoms suggest PE/DVT/ACS/stroke, D-dimer or emergency testing belongs in clinician-directed acute pathways, not routine wellness tracking.

Bottom line: repeat fibrinogen with CBC/CRP/ESR is more useful for trend context than routine D-dimer screening. D-dimer is an acute-diagnostic tool, not a clean baseline risk marker here.

7. What Does This Cluster Tell Us Beyond Gut-Specific Calprotectin?

Calprotectin specifically measures gut mucosal inflammation. The April 2026 results split the old model:

1. Gut inflammatory activity looks quieter — calprotectin normalized to 13.3.
2. Bleeding/iron physiology remains separate — positive FOB/stool RBC and borderline TSAT still need the occult-blood pathway.
3. Systemic inflammatory-thrombotic tone may still exist — ESR/CRP, fibrinogen, WBC/platelets, eczema/allergic activity, smoking, and IgA can all contribute.
4. The platelet-specific pathway has priority — persistent thrombocytosis/leukocytosis should follow the staged workup in Thrombocytosis Workup Pathway.

Clinical significance

The main April 2026 correction is that “gut inflammation driving everything” no longer fits. Calprotectin normalized, yet platelets/WBC did not. The current model should keep three branches separate: stool-blood/iron loss, systemic inflammatory tone, and cardiovascular/thrombotic risk context.

8. Key Takeaways

1. The inflammatory-thrombotic cluster is still real, but it is not simply gut inflammation and not a calculable thrombosis multiplier.
2. The durable-outcome concern is mostly vascular: persistent inflammatory tone can amplify ASCVD/plaque/thrombosis context, which matters more because Lp(a) is already very high.
3. The practical response is ranked risk reduction, not CRP chasing: smoking abstinence, alcohol abstinence while gut/BP signals are live, BP/ApoB/plaque management, and regular exercise outrank supplements.
4. This is not a proven “rapid aging” or “organ damage” diagnosis: current CRP/ESR/fibrinogen are mild/moderate; WBC/platelet persistence is the part that needs repeat CBC/differential/smear logic.
5. ESR/CRP still fit chronic, not acute inflammation, while positive stool blood belongs in its own decision tree.
6. Fibrinogen is now a measured day-0 comparator: 3.7 g/L on 2026-04-26 is high-normal and best interpreted by whether it falls with WBC/platelets after the clean month.
7. IgA remains an isolated abnormality (IgG and IgM are normal); true SPEP/band-pattern confirmation is the missing piece if formal characterization is still wanted.
8. Platelets/WBC own the next hematology branch — use CBC / Thrombocytosis / Inflammation for smear/molecular escalation logic.
9. Occult blood owns the bleeding branch — use GI Bleeding / Diverticular / Stool Blood for FOB/RBC + normal-calprotectin decisions.

Research Trace / Source Anchors

• 2026-05-03 systemic-inflammation intervention hierarchy: PubMed/guideline pass across smoking cessation, alcohol/BP, BP lowering, LDL lowering, exercise, diet pattern, OSA/CPAP, psoriasis treatment, periodontal therapy, CANTOS/colchicine; integration outcome = ranked practical hierarchy here, no new topic.
• CRP and outcome anchors: ERFC individual-participant meta-analysis links higher CRP with CHD, ischemic stroke, vascular mortality, and non-vascular mortality, but attenuates with risk-factor/inflammatory-marker adjustment (PMID: 20031199); CRP/fibrinogen add only modest first-event prediction beyond conventional risk factors (PMID: 23034020).
• Causality/intervention anchor: CANTOS supports inflammatory risk reduction in established post-MI patients with elevated hsCRP, especially when hsCRP falls below 2 mg/L; it does not justify casual anti-inflammatory treatment in this primary-prevention/bleeding-risk context (PMID: 29146124).
• Intervention anchors: smoking cessation improves WBC/absolute-neutrophil and oxidative-stress markers, including biochemically confirmed cessation data showing larger WBC/ANC falls by 52 weeks than continued smoking (PMID: 16092581) and longitudinal check-up data showing current smoking as a reversible WBC-elevation cause (PMID: 27583199); older NHANES marker analysis supports dose/time-related risk-marker improvement after cessation (PMID: 15974805); alcohol reduction lowers BP dose-dependently, mainly above 2 drinks/day baseline (PMID: 29253389); BP lowering and LDL lowering have stronger outcome evidence than marker chasing (PMIDs: 26724178, 21067804); exercise lowers hsCRP in trial meta-analysis (PMID: 26916454); healthy dietary patterns lower inflammatory biomarkers modestly (PMIDs: 34607347, 27101757).
• Source-cleanup anchors: CPAP can lower CRP/IL-6/TNF-alpha when true OSA exists but needs trigger-based screening (PMID: 40346316); psoriasis therapies improve surrogate biomarkers without proven CV event reduction (PMID: 33891953); periodontal treatment has moderate-certainty IL-6/SBP and low-certainty CRP improvement when periodontitis exists (PMID: 38877442), while CVD-event prevention evidence remains very low-certainty (PMID: 36194420).
• Dental/periodontal audit anchors: EFP S3 guideline uses stepwise therapy for stage I-III periodontitis — behavioral/risk-factor control, supra/subgingival instrumentation, possible surgery, and supportive care (PMID: 32383274). Periodontitis is associated with higher CRP in systematic review/meta-analysis (PMID: 34394107), and small observational data link chronic periodontitis with higher WBC/platelet counts (PMID: 23960523); this supports screening if markers persist, not assuming dental disease explains the whole platelet pathway.
• Healthspan anchors: elevated hsCRP predicts all-cause/CV/cancer mortality in observational meta-analysis (PMID: 28327451); inflammaging links inflammation with frailty/multimorbidity but non-CVD intervention proof remains weaker (PMID: 30065258); WBC count is associated with mortality in meta-analysis (PMID: 37506668).
• Profile-specific resolution trigger: repeat clean-month CBC/differential, platelets, CRP/hsCRP, ESR, fibrinogen, iron/stool markers, and smoking/alcohol/skin status decide whether this remains persistent systemic inflammation or downgrades to resolved/confounded inflammatory noise.

Urgent GI Bleeding / Diverticular / Stool Blood

gastrointestinal · diverticular-disease · occult-blood · stool-rbc · ferritin · bleeding · calprotectin · colonoscopy

GI Bleeding / Diverticular / Stool Blood

This is the single current owner for diverticular disease, occult stool blood, rebleeding-risk boundaries, and the bleeding-vs-bloating distinction.

Current conclusion

Current classification: yellow/watch, not red.

Why not red right now: hemoglobin is normal, the 2026-05-27 iron panel improved (ferritin 61.60, TSAT 33.4%), the 2026-05-28 stool repeat was FOB negative with stool RBC absent, fecal calprotectin had normalized to 13.3 µg/g in April, and the retrieved Sept 2024 colonoscopy was complete/high-quality: BBPS 9, terminal ileum reached/examined, normal mucosa, no inflammation, no polyps, no malignancy, normal DRE/perianal/retroflexion findings, with scattered small diverticula from right flexure to sigmoid.

Why not dismiss it completely: April 2026 had FOB positive + stool RBC present. That was an occult GI bleeding signal. It is not proof of diverticular rebleeding, not explained by SIBO/bloating, and not erased retroactively by a later negative test. Late 2025 is weaker as bleeding evidence: ferritin reached 35.28 during likely heavy alcohol/smoking exposure, but stool occult blood and stool RBC were negative on 2025-12-23.

Historical context is preserved but should not drive current decisions by itself: the August 2025 visible-bleeding stool-photo comparator is privately archived; a reported pre-bleed OTC topical mupirocin genital exposure is also privately archived and graded low-plausibility/temporal-only as a lower-GI bleeding cause.

What changes the decision

What to do now

What not to do

Evidence and owner links

• Emergency/whole-profile red flags: Whole-Profile Seriousness Triage, Recurrence Action Plan.
• Iron interpretation: Iron, B12 & Malabsorption.
• Medication safety: Medication List + Hard Avoids, ASCVD / Lp(a) Prevention Master.
• Symptom/motility owner: Bloating / Motility / SUDD-SIBO Symptom Plan.
• Post-experiment result routing: Post-Experiment Decision Router.

Preserved evidence anchors include diverticular bleeding/rebleeding reviews (PMID: 40012838; PMID: 38989865; PMID: 40109318; PMID: 40542969; PMID: 40865763), diverticular diet/fiber evidence (PMID: 33919755; PMID: 40651334; PMID: 39976023), exercise/diverticular evidence (PMID: 23668524), alcohol/smoking meta-analysis context (PMID: 41760075), occult blood/FIT/gFOBT logic (PMID: 23547576; PMID: 34003218; PMID: 25492500; PMID: 10022627; Cochrane PMC9169237), IDA guidance (PMID: 32810434; PMID: 34497146), small-bowel bleeding guidance (PMID: 26303132), CTA active-bleeding pathway (PMID: 36735555), and calprotectin/diverticular inflammation literature (PMID: 18941760; PMID: 22572679).

Urgent Bloating / Motility / SUDD-SIBO Symptom Plan

bloating · motility · sibo · mmc · sudd · ibs · abdominal-pain · probiotics · cbm588 · bile-acid-diarrhea · diet-soda

Bloating / Motility / SUDD-SIBO Symptom Plan

Current conclusion

The active pattern belongs in a symptom/motility branch, not the bleeding branch:

• prominent post-prandial bloating/distension
• brief, low-grade, migrating spot pains, usually seconds to minutes and around 2-3/10
• location changes: lower left, lower right, center/lower abdomen, left of belly button, far right, occasional upper-left/chest-tightness note
• bloating often around 5-7/10 during pain observations
• normalized calprotectin, which weakens active inflammatory colitis/diverticulitis as the main bloating explanation
• no documented fever, guarding, persistent same-site pain, visible blood, or hemodynamic bleeding symptoms in the spot-pain observations

Most plausible symptom labels: SIBO/MMC dysfunction, SUDD/IBS overlap, fermentation load, meal stacking, carbonation/diet-soda exposure, coffee sensitivity, visceral hypersensitivity, abdominal-wall/position effects, or alcohol/smoking destabilization. Bile-acid diarrhea stays lower priority unless logs show repeated watery urgency/high-frequency stool. The final-week coffee plan became reduced coffee with logged exceptions, so it is useful context but not a clean no-coffee trigger-removal test.

Boundary rule: SIBO/SUDD/probiotics do not explain positive FOB/stool RBC or iron drift. Positive stool blood, visible blood, Hb/ferritin/TSAT decline, melena, dizziness/faintness, or repeat stool-RBC positivity stay owned by GI Bleeding / Diverticular / Stool Blood and Iron, B12 & Malabsorption.

What changes the decision

Testing rules:

• Hydrogen/methane breath testing is reasonable only if accessible and if the result would change treatment. Minimum useful result reports hydrogen and methane; consensus anchors: hydrogen rise >=20 ppm by 90 minutes, methane >=10 ppm at any point, with elevated fasting baseline as supportive context.
• Glucose breath test has better specificity but may miss distal SIBO. Lactulose can sample distal fermentation but is more transit-confounded. Trio-gas/H2S is nice-to-have, not locally required.
• Jejunal aspirate is not a default step.
• BAD testing belongs only to repeated watery urgency / IBS-D-like logs, not isolated bloating.
• Broad commercial stool microbiome testing is not a core decision tool.

Local access status: no confirmed public Phnom Penh hydrogen/methane SIBO breath-test provider and no confirmed public bile-acid diarrhea test route. Biomed tariff scrape did not show breath/hydrogen/methane/SIBO, SeHCAT, serum C4, FGF19, or fecal-bile-acid testing. Ask a Phnom Penh GI directly before building plans around these tests; Bangkok remains fallback only if a formal result would change treatment.

What to do now

1. Keep this branch log-driven after the clean experiment: meal timing, 4-5h water-only gaps when practical, no grazing, bloating onset/peak, morning baseline vs post-meal peak maximum-width abdomen circumference, stool pattern/photo, pain location/duration/intensity, walking/toilet/gas relation, weight trend, alcohol/smoking status, coffee/tea type and size, Coke Zero/diet soda/carbonation, and large/stacked meals.
2. While the diet-soda signal is live, avoid Coke Zero/diet colas rather than using them as coffee/alcohol substitutes. If re-challenged later, test one variable at a time: volume, carbonation, caffeine/cola acid, and non-caloric sweetener are otherwise mixed together.
3. Use low-risk symptom trials before medications:
   • meal spacing / no caloric snacks
   • reduce meal stacking and large boluses
   • time-limited low-fermentable / modified low-FODMAP trial only if symptoms remain disruptive after the main experiment, with reintroduction rather than permanent restriction
   • fiber tuning, not fiber fear; psyllium only as a low-start slow-titrate trial if stool regularity/fiber consistency is the target
   • one probiotic strategy at a time if logs show benefit
4. Probiotic position:
   • Probiotics are symptom-management tools for SUDD/IBS-like overlap, not bleeding prevention or general anti-inflammatory therapy.
   • A broad base probiotic is reasonable only if logs show benefit; do not run multiple probiotics indefinitely because each has a plausible mechanism.
   • S. boulardii is mainly diarrhea-oriented; rare fungemia risk matters in ICU/central-line/severe immunocompromise settings.
   • CBM588/Miyarisan is a plausible targeted trial for SUDD-type abdominal symptoms, but only if the exact Miyairi/CBM588 strain can be sourced. Ask for “Miyarisan / Miyairi 588 / Clostridium butyricum CBM588,” product photo, ingredient/strain label, and expiry date. Generic C. butyricum is not automatically the studied strain.
5. If symptoms persist enough for a GI visit, ask one focused question: can they arrange hydrogen + methane testing, bile-acid testing when watery urgency dominates, or would they manage empirically after red flags and bleeding branch issues are excluded?

What not to do

• Do not use SIBO/MMC, probiotics, CBM588, or bloating improvement to explain away stool blood or iron drift.
• Do not use CT abdomen/pelvis for routine bloating. Reserve CT for acute diverticulitis/complication signs, severe or persistent focal pain, fever, obstruction, abscess concern, unexplained weight loss, or clinician-directed structural concern.
• Do not self-start rifaximin, neomycin, prokinetics, mesalazine, bile-acid sequestrants, or antibiotics for brief migrating 2-3/10 pains. Rifaximin is usually a clinician discussion for hydrogen-predominant SIBO; rifaximin + neomycin is methane/IMO logic but neomycin has ototoxicity/nephrotoxicity concerns; prokinetics such as prucalopride/low-dose erythromycin require interaction/QT review; bile-acid sequestrants can worsen bloating/constipation and bind other medicines/supplements.
• Do not make diet permanently restrictive based on one flare. Use short trials with reintroduction.
• Do not chase commercial microbiome sequencing, fecal SCFA panels, TMAO narratives, or histamine narratives as core next steps.
• Do not stack base probiotic + S. boulardii + CBM588 indefinitely without log-visible benefit.
• Do not use NSAIDs for abdominal pain unless a clinician deliberately accepts the bleeding risk.

Evidence and owner links

• Current owner: Bloating / Motility / SUDD-SIBO Symptom Plan.
• Absorbed detail covered here: spot-pain mapping, probiotics, and CBM588.

Evidence anchors retained from the absorbed pages:

• Breath-test consensus and interpretation: PMID: 28321120; PMID: 36214973.
• BAD guidance/reviews/testing/treatment: PMID: 32010878; PMID: 29653941; PMID: 32558690; PMID: 28691284; PMID: 36758570; PMID: 37771793.
• Diverticular/SUDD microbiome, bile-acid, pain, and overlap context: PMID: 15884120; PMID: 27622371; PMID: 39514266; PMID: 40703297; PMID: 39093005; PMID: 37013200; PMID: 24583746; PMID: 18941760; PMID: 22276853; PMID: 33867449; PMID: 30407258.
• Diverticulitis imaging/red-flag context: PMID: 33279517.
• IBS/low-FODMAP selected-trial support: PMID: 33315591.
• SIBO treatment/relapse/MMC context: PMID: 21083027; PMID: 22340737; PMID: 31515325; PMID: 1687562; PMID: 10603298; PMID: 27507954.
• Diet-soda/NCS/carbonation context: PMID: 19502016; PMID: 22676475; PMID: 31564473; PMID: 35268070; PMID: 33171964; PMID: 37111090.
• Probiotics in diverticular disease/SUDD: PMID: 41517338; PMID: 41443984; PMID: 27622371.
• CBM588 SUDD study: PMID: 41108431.
• S. boulardii safety/efficacy: PMID: 22423260; PMID: 36806741.
• Adult atopic-dermatitis probiotic signal: PMID: 40740395; PMID: 37706436.
• Microbiome-testing consensus: PMID: 39647502.

This page is the canonical symptom/pain/motility owner. Spot-pain, probiotic, and CBM588 decisions should be read here rather than as separate pages.

Important Iron, B12 & Malabsorption

hematology · iron-deficiency · ferritin · transferrin-saturation · gi-bleeding · oral-iron · b12 · homocysteine · celiac · autoimmune-gastritis · malabsorption · vegetarian-diet

Iron, B12 & Malabsorption

Current conclusion

The current state is not iron-deficiency anemia, and not a proven malabsorption syndrome. The useful frame is narrower:
- ferritin previously fell from about 94 to 35 ug/L; late-2025 is now exposure-confounded by likely heavy alcohol/cigarette use, and the next-day 2025-12-23 stool occult blood/RBC test was negative
- April 2026 was different: ferritin was 54.01 with positive stool occult blood + stool RBCs, so that round remains the clearer occult-blood signal
- the 2026-05-12 midpoint draw showed ferritin 43.28 ug/L and TSAT 27.7% under non-fasting post-meal/coffee conditions; the 2026-05-27 end summary then improved to ferritin 61.60 and TSAT 33.4% after zero alcohol/smoking
- hemoglobin has remained normal in the available series
- CRP is normal, so ferritin is not obviously being inflated by acute inflammation
- the stool occult blood / stool RBC branch cooled on 2026-05-28 (FOB negative, stool RBC absent), but recurrence rules still apply because April 2026 was a real stool-positive signal
- B12 is low-normal and recurrently near the lower range: 231 pmol/L on 2026-04-19, with prior values 396, 279, 193, 228, 291 pmol/L
- homocysteine has been upper-normal around 10.6-11.9 μmol/L; folate has historically been adequate
- no current macrocytic anemia signal, but NICE 2024 explicitly says normal hemoglobin/MCV does not rule out B12 deficiency
- old tTG-IgA was negative in 2015; total IgA is high rather than deficient; gastrin was normal in April 2026

Bottom line: repeat trends and source clarification come first. Supplements can run in parallel when justified, but they must not hide whether bleeding or absorption problems persist.

What changes the decision

What to do now

1. If stool follow-up is not already done, repeat the useful trend set rather than chasing isolated serum iron: CBC with indices/RDW, ferritin, serum iron, TIBC or transferrin, TSAT, CRP, and stool-blood/direct-exam follow-up as owned by GI Bleeding / Diverticular / Stool Blood.
2. Do not make oral iron automatic from the April snapshot. If ferritin/TSAT drift again or symptoms justify repletion, use a conservative regimen:
   • ferrous bisglycinate if available/tolerated; otherwise sulfate/fumarate/gluconate are acceptable but often harsher
   • 25-36 mg elemental iron every other day to start; consider 45-65 mg only if response is poor and tolerated
   • morning empty stomach if tolerated, otherwise with a small non-calcium snack
   • optional vitamin C / fruit support
   • separate from coffee/tea, calcium, magnesium, zinc, high-fiber supplements, antacids/PPIs if avoidable, and psyllium by about 2 hours or more
   • reassess ferritin/TSAT/Hb after 6-8 weeks
3. Define oral-iron success before starting:
   • ferritin rises about 10-30 ug/L, TSAT improves, Hb stable = useful repletion response
   • ferritin rises but stool blood persists = tablets are repleting, but source branch remains active
   • no ferritin/TSAT response = ongoing loss, poor adherence/timing, malabsorption, wrong dose/form, or inflammation/sequestration
   • Hb falls despite iron = escalate
4. B12: because diet is vegetarian-leaning and B12 is repeatedly low-normal, simple oral support is reasonable without a large panel:
   • no clear neurologic symptoms: 1000 mcg cyanocobalamin or methylcobalamin 2-3x/week, or 250-500 mcg/day
   • compatible symptoms: 1000 mcg/day for 8-12 weeks, then step down if symptoms/labs improve
   • recheck B12 + homocysteine + folate in 8-12 weeks if this becomes an active experiment
   • MMA is useful only if accessible or symptoms persist despite adequate oral B12
5. Malabsorption/celiac: do not automatically add a broad panel. If triggered, ask for the exact test tTG-IgA / anti-TG2 IgA while eating gluten. Add total IgA only if the lab requires same-day pairing; IgA deficiency is already ruled out by elevated total IgA.
6. Autoimmune gastritis/pernicious branch: do not shotgun now. Trigger only if B12/iron behavior worsens or fails to respond, gastrin rises, upper-GI symptoms appear, or gastroscopy is being done anyway. If scoped, ask for gastric body + antrum/incisura biopsies in separately labelled jars plus H. pylori assessment.

Local availability reminders:

What not to do

• Do not let iron supplementation make the diagnostic branch disappear. A ferritin bump from tablets does not prove bleeding stopped.
• Do not treat black/dark stool on oral iron as proof of bleeding; also do not dismiss visible blood or positive FOB as “just the iron” without clinical/lab context.
• Do not delay stool-blood/GI-source workup because oral iron is possible.
• Do not run a broad autoimmune/malabsorption panel for bloating alone.
• Do not self-diagnose celiac by going gluten-free before testing; negative serology after gluten restriction is unreliable.
• Do not substitute HLA-B27 or generic IgA/IgG tests for celiac-specific testing.
• Do not use B12 injections by default; reserve clinician/IM-route logic for objective neurologic signs, poor oral response, or strong malabsorption/pernicious concern.
• Do not add high-dose B6 casually; chronic excess can cause neuropathy and muddy symptom interpretation.
• Do not use IV iron as default. It becomes a clinician discussion if oral iron is not tolerated, ferritin/TSAT fail to respond after 6-8 weeks with good adherence/timing, Hb declines/symptomatic anemia develops, or malabsorption/ongoing loss makes oral repletion unrealistic.

Evidence and owner links

• Current owner: Iron, B12 & Malabsorption.
• Absorbed detail covered here: oral iron, celiac/autoimmune-gastritis screening, and B12 follow-up.

Evidence anchors retained from the absorbed pages:

• Iron deficiency / GI evaluation: AGA IDA guideline PMID: 32810434; BSG IDA guideline PMID: 34497146; AGA Clinical Practice Update on IDA PMID: 38864796; non-anaemic iron deficiency review PMID: 34908363; serum iron variability PMID: 12090432.
• Oral iron dosing/tolerability: hepcidin physiology PMID: 26289639; alternate-day absorption PMID: 31413088; alternate-day RCT PMID: 36725875; daily-vs-alternate systematic review PMID: 37979057.
• B12 framework: NICE NG239 (2024), Vitamin B12 deficiency in over 16s: diagnosis and management, https://www.nice.org.uk/guidance/ng239.
• Adult celiac diagnosis: ESsCD 2025 guideline PMID: 40999951; ACG 2023 guideline update PMID: 36602836.
• Autoimmune/atrophic gastritis: AGA atrophic gastritis clinical practice update PMID: 34454714; autoimmune gastritis clinical management review PMID: 34484423; corpus-restricted atrophic gastritis biomarker study PMID: 36428844.

This is the canonical iron/B12/malabsorption owner. Oral iron, B12, celiac, and autoimmune-gastritis decisions should be read here rather than as separate pages.

Monitor Endocrine / Vitamin Watchlist

calcium · PTH · parathyroid · vitamin-D · vitamin-K2 · hypercalcemia · vascular-calcification · thyroid · tsh · subclinical-hypothyroidism · TPO-antibodies

Endocrine / Vitamin Watchlist

Current conclusion

This cluster is a watchlist, not a current endocrine diagnosis.

Calcium/PTH/vitamin D:

• total calcium has been high-normal for years, with one older 2.55 mmol/L value in 2015 and recent values around 2.47-2.50 mmol/L
• albumin has sometimes been high, which can push total calcium up without proving high ionized calcium
• PTH was elevated once in 2022 with only modest vitamin-D status, then normalized by 2024
• 25(OH)D is about 105 nmol/L, already sufficient and below toxicity-concern ranges
• current NOW product: 1,000 IU D3 + 45 mcg K2 as MK-4 per capsule; 2/day = 2,000 IU D3 + 90 mcg MK-4

Thyroid:

• the old “monotonic rise” story is broken: TSH moved 1.5 (2015) / 1.4 (2018) / 2.0 (2024-08) / 2.65 (2025-10) / 2.82 (2025-11) / 3.61 (2025-12) back down to 1.75 (2026-04)
• free T4 has historically been normal
• atorvastatin dose reduction from 40 mg to 20 mg occurred before normalization, but causality is unproven
• true hypothyroidism can worsen atherogenic risk and possibly Lp(a)-related context, but current data do not support thyroid dysfunction as an active risk amplifier

Bottom line: maintain, pair-check if rechecking, and do not chase higher vitamin D, K2, or thyroid testing while more actionable GI/hematology/cardiovascular branches are live.

What changes the decision

What to do now

1. Keep vitamin D in maintenance mode. Do not push 25(OH)D higher than the current sufficient range.
2. If rechecking the calcium/PTH axis, draw the paired set on the same day: calcium, albumin, PTH, 25(OH)D, phosphorus, creatinine/eGFR. Ionized calcium is useful if available.
3. Biomed public tariff context from 2026-05-03: serum calcium, albumin, phosphorus, PTH/iPTH, and 25(OH)D are listed; ionized calcium and serum vitamin K were not found.
4. K2 form/label hygiene is fine, but switching MK-4 to MK-7 is optional supplement tidying, not cardiovascular treatment.
5. Treat aortic-valve surveillance as an Lp(a) imaging issue: baseline echo first; K2 is not a substitute.
6. Thyroid: recheck TSH with routine follow-up bloodwork. Add free T4/TPO only if TSH rises again, symptoms strongly fit hypothyroidism, or the autoimmune-thyroid question is worth closing after higher-priority branches settle.

What not to do

• Do not diagnose primary hyperparathyroidism from high-normal total calcium alone.
• Do not ignore albumin/corrected or ionized calcium when total calcium is borderline.
• Do not chase vitamin D above sufficiency; no current reason to target “higher is better.”
• Do not use vitamin K2 as claimed protection against Lp(a)-related valve disease, CAC, or ASCVD events.
• Do not order serum vitamin K as a routine cardiovascular marker.
• Do not treat one normalized TSH fluctuation as active thyroid disease.
• Do not blame atorvastatin for the old TSH rise as a conclusion; it remains plausible background context only.
• Do not let thyroid/K2 speculation distract from echo, BP, ApoB/Lp(a) management, smoking cessation, GI bleeding/iron follow-up, and imaging decisions.

Evidence and owner links

• Current owner: Endocrine / Vitamin Watchlist.
• Absorbed detail covered here: calcium/PTH/vitamin D, vitamin K2, and TSH trend logic.

Evidence anchors retained from the absorbed pages:

• Primary hyperparathyroidism evaluation/management: PMID: 36245251.
• NIH ODS Vitamin D fact sheet, updated 2025: adequacy >=50 nmol/L; possible adverse associations above 125 nmol/L, especially above 150 nmol/L.
• 2024 Endocrine Society vitamin-D prevention guideline: PMID: 38828931.
• Vitamin K vascular/calcification evidence: PMID: 37252246; PMID: 38046003; AVADEC vitamin K2 + D aortic-valve calcification RCT PMID: 35465686.
• Lp(a) and calcific aortic valve disease: PMID: 37650693.
• Thyroid management frame: NICE NG145, Thyroid disease: assessment and management, https://www.nice.org.uk/guidance/ng145.
• NOW Foods Vitamin D3 & K2 product page: https://www.nowfoods.com/products/supplements/vitamin-d3-k2-capsules.

This is the canonical endocrine/vitamin owner. Vitamin D/K2 and TSH decisions should be read here rather than as separate pages.

Urgent Elevated IgA Workup

IgA · immunoglobulins · SPEP · monoclonal-gammopathy · inflammation · liver · renal · celiac

Elevated IgA Workup

Bottom line

IgA fell from 634.7 mg/dL to 546.6 mg/dL on 2026-05-28, still about 1.13x the upper reference limit. That is a real abnormality, but by itself it is not a myeloma-level signal and should not trigger a maximal hematology panel on day one.

The warranted workup is now narrower:

1. Resolved reassuring pieces: IgG 1299 mg/dL and IgM 72.5 mg/dL are normal; urine analysis is clean; hemoglobin electrophoresis is normal.
2. Newly clarified: the 2026-05-28 protein electrophoresis result appears to be the true SPEP-style test, not the earlier hemoglobin electrophoresis. The preserved graph has no obvious narrow M-spike; albumin is dominant, gamma is broad/normal-quantity, and beta-1/beta-2 fractions are mildly high.
3. If clinician/lab interpretation agrees SPEP is non-suspicious/polyclonal-looking: treat IgA as a reactive/source-finding and trend-monitoring problem, not a hematology alarm.
4. If SPEP is re-read as suspicious or IgA rises: add serum immunofixation/free light chains by clinician direction.

Urine analysis is already reassuring: no protein, no blood, and urine WBC/RBC within Biomed range. Normal IgG and IgM are also reassuring. The earlier hemoglobin electrophoresis was a red-cell hemoglobin test, not a serum-protein pattern test; the 2026-05-28 protein electrophoresis now supplies the first-pass serum-protein pattern context.

“Urgent” here means high-priority KB tracking, not emergency care unless the red flags listed in Whole-Profile Seriousness Triage appear.

Why SPEP matters more than repeating IgA

Quantitative IgA tells the amount. It does not tell whether the excess is broad/polyclonal or a narrow clone.

First-pass tests at Biomed

These are available and enough for the first decision point:

The useful low-cost clarification is now mostly reassuring: IgG/IgM and urine are normal; hemoglobin electrophoresis is normal but answers a different question; and the true protein electrophoresis/SPEP-style result does not show an obvious narrow spike. The remaining task is trend plus formal interpretation, not automatic expensive escalation.

Tests to hold unless triggered

Biomed has these, but they are not the default first-pass spend for a moderate isolated IgA elevation:

CAP guidance for suspected monoclonal gammopathy supports SPEP plus serum free light chains as the sensitive initial screen, with immunofixation when SPEP or sFLC is abnormal. The key qualifier is “suspected monoclonal gammopathy”; a single moderate IgA elevation without CRAB-style features can reasonably start with lower-cost pattern triage.

Source buckets if SPEP is polyclonal

Polyclonal hypergammaglobulinemia is usually secondary to another condition. Reviews group causes into liver disease, autoimmune/vasculitis, infection/inflammation, malignancy, hematologic disorders, IgG4-related disease, immunodeficiency, and iatrogenic immunoglobulin therapy. Liver disease, immune dysregulation, and inflammation are the big common buckets.

For this profile, rank the practical causes like this:

1. Reactive/inflammatory tone — eczema/allergic disease, smoking, chronic low-grade inflammatory pattern, and the platelet/WBC/ESR context make this plausible.
2. Gut disease / mucosal immune activation — SUDD/diverticular disease and occult stool blood are relevant, but normalized calprotectin argues against active high-grade gut inflammation right now.
3. Liver/alcohol history — IgA can rise with alcohol-related and chronic liver disease, but current AST/ALT/GGT/bilirubin and low FIB-4 make advanced liver disease a weak explanation. Re-open if ALP/GGT/AST/ALT change, ultrasound shows steatosis/chronic-liver signs, or FibroScan is abnormal.
4. Celiac disease / malabsorption — old tTG-IgA was negative in 2015 and total IgA is high rather than deficient. Re-open only by trigger using Celiac + Autoimmune Gastritis + Malabsorption Screen, not as a reflex explanation for IgA alone.
5. Chronic infection/immune disease — HIV is repeatedly negative. Hepatitis B/C status matters if not current; autoimmune screens should be symptom-triggered, not shotgun.
6. Plasma-cell / lymphoproliferative disorder — lower probability from IgA alone, but cannot be excluded without SPEP pattern recognition.

Red flags that change the plan

Escalate beyond passive monitoring if any of these appear:

• SPEP monoclonal spike or suspicious beta-region restriction
• Abnormal immunofixation or abnormal serum free light-chain ratio
• New anemia not explained by iron/bleeding, rising creatinine/eGFR decline, hypercalcemia, or bone pain/lytic lesion concern
• Proteinuria/albuminuria or unexplained renal findings
• IgA rising substantially on repeat, especially if isolated
• Constitutional symptoms, lymphadenopathy, recurrent/unusual infections, or unexplained weight loss

Key takeaways for this profile

• What changed: IgA fell but remains high; IgG and IgM are normal, urine is clean, hemoglobin electrophoresis is normal, and the true protein electrophoresis/SPEP-style follow-up does not show an obvious narrow M-spike.
• What did not change: IgA remains an unexplained moderate isolated elevation that deserves trend monitoring and source thinking.
• Critical distinction: the older Hb A/Hb A2 hemoglobin electrophoresis did not answer the SPEP question; the 2026-05-28 protein electrophoresis now does provide the relevant first-pass band-pattern screen.
• Do not do by default: $80 immunofixation or $130 free light chains unless SPEP is suspicious, clinician wants a full screen, IgA rises, or urine/basic labs/red flags change.
• If the SPEP pattern is formally read as non-suspicious: a reasonable low-drama option is repeat quantitative immunoglobulins later and escalate only if IgA rises, total protein/globulin changes, or symptoms/red flags appear.

Research trace

• Date: 2026-04-25. Question type: diagnostic / testing pathway.
• Sources checked: current cloud doc; KB index, research queue, planned test plan, inflammatory-thrombotic topic; Biomed tariff list; PubMed/web review sources.
• Evidence anchors: Lancet Haematology review on adult polyclonal hypergammaglobulinemia (PMID: 33894171); NCBI Bookshelf/StatPearls polyclonal gammopathy summary; Scientific Reports 2024 Bordeaux cohort/algorithm for significant polyclonal hypergammaglobulinemia; CAP 2024 clinician handout for monoclonal gammopathy lab workup.

Important Eczema-Diverticular Connection

eczema · psoriasis · atopic-dermatitis · diverticular-disease · skin-gut-axis · gut-microbiome · inflammation · IBD · calprotectin · barrier-dysfunction

Eczema-Diverticular Disease Connection

Summary

The practical model is evidence-tiered, not “eczema causes diverticular disease.”

Dag’s history does support a skin-gut hypothesis: chronic eczema/psoriasis-overlap, dry eyes/meibomian blockage, IgE elevation, gut symptoms, alcohol sensitivity, and eczema improvement during diet/probiotic periods. But April 2026 also limits the claim: calprotectin is now normal, while occult blood and platelet/WBC issues persist. That means skin/allergic activity may contribute to systemic inflammatory tone, but it should not be used to explain stool blood or diverticular bleeding.

Evidence tiers

Microbiome actionability — useful vs noisy

Classification: INTEGRATE. The gut-heart-skin microbiome queue item resolves here as a practical filter across the existing SIBO, probiotic, skin-gut, inflammatory, and supplement pages. The current evidence supports low-risk pattern work, not broad microbiome diagnostics.

Current signal

Relevant personal signals:

• chronic eczema/psoriasis-overlap with steroid-responsive recurrence
• dry-eye/meibomian involvement compatible with skin/barrier disease
• IgE historically elevated, consistent with allergic/Th2 tone
• prior calprotectin elevation has normalized to 13.3 ug/g
• stool occult blood and stool RBCs now exist despite normal calprotectin
• platelets/WBC remain active enough to need their own workup pathway
• vegetarian/fiber/probiotic periods coincided with eczema improvement
• alcohol worsens stool looseness and plausibly worsens gut barrier/sleep/BP noise

The important split: skin/allergy may still be active while gut mucosal inflammation is quiet. Do not collapse those into one “gut inflammation” story.

Action implications

Tests such as tryptase, zonulin, or fecal SCFA are not core next steps unless a clinician or specific symptom pattern would act on them. Dermatology review has higher practical yield than adding speculative gut-barrier markers.

Evidence / context

Microbiome actionability anchors

• Broad stool microbiome testing is not ready as a general decision tool. A 2025 international consensus states that clinical usefulness remains scarce/limited and warns that direct-to-consumer testing can waste resources and drive inappropriate interventions. PMID: 39647502.
• Fiber/whole-food pattern remains the highest-yield microbiome lever. A 2025 human review supports modest anti-inflammatory effects for high-fiber diets, with inulin and resistant starch showing clearer short-term signals, but not enough precision to prescribe a single fiber type by test result. PMID: 40076626.
• TMAO is an associated CVD biomarker in meta-analysis, but it is not a practical substitute for Lp(a), ApoB/LDL, BP, smoking, or plaque/valve imaging decisions. PMID: 29020409.
• Histamine intolerance lacks a validated biomarker and should be handled only as a reproducible food-response pattern, not as a default unifying gut-skin diagnosis. PMID: 41009760.

Established / stronger anchors

• AD and IBD association is supported by large meta-analyses; effect sizes are real but not automatically large enough for personal prediction. PMID: 39678631, PMID: 39602916.
• Mendelian randomization supports a possible causal AD -> IBD relationship, but this is not evidence for AD -> diverticular bleeding. PMID: 34964870.
• AD associates with broader autoimmune comorbidity, especially with more severe disease. PMID: 35469843.

Plausible but not decisive

• Gut-skin reviews support microbiome, barrier, SCFA, oxidative-stress, and immune-crosstalk mechanisms. These mechanisms fit symptom co-movement without establishing structural diverticular outcomes. PMID: 41269405, PMID: 38623584, PMID: 41897446.
• JAK/STAT and overlapping cytokine pathways matter in both skin and intestinal immune disease, but shared drug classes are not proof of one shared diagnosis.

Weak / speculative for this KB

• The psoriasis-diverticulitis signal is small and observational (reported HR/relative risk around 1.16 in one cohort). It is not a bleeding-risk rule and should not dominate management. PMID: 31039227.
• A 2026 Taiwan AD/IBD case-control signal is hypothesis-generating and does not justify changing diverticular strategy by itself. PMID: 41858144.

Bottom line

Use eczema as a clue about systemic/allergic tone and as a reason to keep microbiome/diet experiments evidence-tiered. Do not let it become a unifying explanation for everything. Positive stool blood goes to the bleeding workup; persistent thrombocytosis goes to the platelet pathway; bloating goes to SIBO/SUDD symptom tracking; eczema gets its own dermatology/skin-barrier management.

Important Supplement Decision Ledger

supplements · probiotics · omega-3 · vitamin-d · fiber · psyllium · homocysteine · b12 · iron · magnesium · zinc

Supplement Decision Ledger

Current conclusion

The supplement stack should shrink, not grow. Supplements are allowed only when they answer a named branch:

• vitamin D sufficiency / calcium-PTH monitoring
• modest omega-3 maintenance
• logged probiotic symptom response
• B12/homocysteine follow-up
• magnesium or zinc only for a specific target
• tolerated fiber/psyllium titration
• iron repletion only when the stool-blood/iron branch justifies it

Current medication/supplement safety details live in Medication List + Hard Avoids. Antiplatelet/aspirin tradeoffs now live in ASCVD / Lp(a) Prevention Master. Clinical interpretation stays with the owner topics: Bloating / Motility, Iron, B12 & Malabsorption, and Endocrine / Vitamin Watchlist.

What changes the decision

Omega-3 specifics:

• current roughly 600 mg/day EPA+DHA is acceptable maintenance
• escalation toward 1.5-2 g/day is optional and currently low-yield
• avoid self-directed 3-4 g/day or high-dose purified EPA strategies in a prior diverticular-bleed profile unless a specialist gives a specific reason
• standard supplemental doses appear low bleeding-risk; higher bleeding signal is concentrated in very-high-dose purified EPA
• fish oil vs krill oil matters less than total EPA+DHA delivered and tolerance

What to do now

1. Keep fish oil and D3/K2 steady. Do not escalate either to chase Lp(a), valve disease, CAC, bloating, or generic inflammation.
2. Stop/avoid turmeric+piperine and broad “anti-inflammatory” botanical stacking during the clean experiment.
3. If stable, trial stopping daily S. boulardii for 2-4 weeks while keeping the base multi-strain product unchanged; keep only what the logs justify.
4. Do not start psyllium just to chase bloating/pain while stool firmness is consistently good. Keep it as a later low-dose trial only if the explicit target is fiber consistency, travel backup, stool regularity, or modest LDL/ApoB hygiene.
5. Psyllium protocol if used:
   • plain husk powder/capsules, not stimulant-laxative blends or sugar-heavy mixes
   • start 2-3 g/day for 3-4 days, then 5 g/day if tolerated
   • only move toward 7-10 g/day if stool/bloating logs improve and gas/distension do not rise
   • mix each dose with at least 240 mL water and drink promptly; never take dry powder
   • separate from prescription medicines and key supplements by about 2-3 hours; be stricter around iron, thyroid meds if ever used, digoxin/salicylates/nitrofurantoin, and minerals
   • stop/do not start during acute severe abdominal pain, vomiting, suspected obstruction, difficulty swallowing, unexplained worsening pain, or new visible bleeding
6. Add B12/B-complex, magnesium, zinc, or iron only when the relevant owner topic says the trigger is present. Add one thing at a time so the logs stay interpretable.

What not to do

• Do not add several items at once. The logs become unreadable.
• Do not treat supplements as a workaround for unresolved stool blood, iron drift, severe Lp(a), BP, smoking, or imaging decisions.
• Do not frame K2 as proven Lp(a)-valve/CAC protection.
• Do not frame omega-3 escalation as Lp(a) therapy.
• Do not treat probiotics, CBM588, psyllium, or S. boulardii as bleeding prevention.
• Do not use oral iron unless the iron/stool-blood branch justifies it, and do not interpret a ferritin bump as proof bleeding stopped.
• Do not use chronic high-dose B6 casually.
• Do not use broad commercial microbiome testing as a supplement selector.
• Do not use psyllium during new visible bleeding or obstructive/severe abdominal symptoms; those are clinician branches.

Evidence and owner links

• Current owner: Supplement Decision Ledger.
• Absorbed detail covered here: omega-3 maintenance/escalation boundaries.

Related clinical detail stays with Bloating / Motility, Iron, B12 & Malabsorption, and Endocrine / Vitamin Watchlist.

Evidence anchors retained:

• Turmeric safety: NCCIH turmeric page; LiverTox turmeric monograph, updated 2025-06-16, treating turmeric as a rare but documented cause of clinically apparent liver injury, especially high-bioavailability/piperine formulations.
• Vitamin B6 upper-limit review / neuropathy signal: PMID: 37207271.
• Omega-3 bleeding-risk meta-analysis: PMID: 38742535.
• Omega-3 and arterial inflammation in elevated Lp(a): PMID: 37598001.
• Krill vs fish-oil evidence: PMID: 37413768; PMID: 32073633.
• Probiotics/diverticular disease: PMID: 41517338; PMID: 41443984.
• B12 supplementation/route evidence: PMID: 37495210; PMID: 38231320.
• Vitamin D/K2 escalation boundary: PMID: 38828931; PMID: 35465686; PMID: 37252246.
• Psyllium LDL/non-HDL/ApoB meta-analysis: PMID: 30239559.
• SUDD/fiber context: PMID: 37013200.
• AGA acute diverticulitis guidance: fiber-rich diet or supplementation; avoid nonaspirin NSAIDs when possible.
• AGA/ACG chronic idiopathic constipation guideline, 2023: fiber supplementation conditional; psyllium has the clearest fiber-supplement evidence; hydration and flatulence caveat.
• FDA 21 CFR 101.81: 7 g/day soluble fiber from psyllium husk may be used in CHD-risk health claims when part of a low saturated-fat/cholesterol diet.
• MedlinePlus psyllium page, revised 2024-06-20: 240 mL fluid per dose, inhalation/allergy and medication-timing cautions.

This is now the supplement hub. Omega-3, vitamin D/K2, B12, iron, probiotic, CBM588, and psyllium decisions should be read here or in the linked clinical owner.

Explorer Meal Tracker Event Browser

Meal Tracker events load from the external read-only data script; enable JavaScript to render the event browser.

Explorer Blood Test Explorer

32 test dates · 163 markers tracked · 2015-2026

Explorer Apple Health Explorer

Apple Health data loads from the external summary script; enable JavaScript to render the imported record/window counts.

Important Apple Health Signal Mining

apple-health · wearable · resting-heart-rate · HRV · sleep · smoking · alcohol · ferritin · lpa

Apple Health Signal Mining

What the imported data can and cannot answer

The import is already useful, but uneven.

• Daily activity coverage is excellent across the full archive.
• The high-value wearable physiology starts much later.
• The exact post-bleed / ferritin-drop window that would have been most interesting (late Aug through Oct 2025) has poor coverage for sleep, resting HR, HRV, respiratory rate, and oxygen saturation.
• Coverage becomes good from Nov 2025 onward, which is enough for trend work and exposure tagging.

Coverage in the most relevant windows

Implication: the archive is strong enough for smoking/alcohol/recovery analysis from Nov 2025 onward, but weaker for reconstructing the immediate physiologic response to the Aug 2025 bleed.

Strongest personal signal already visible: smoking/autonomic stress

The cleanest new pattern is the shift from the late-2025 smoke-free window to the spring-2026 relapse window.

Late-2025 smoke-free vs spring-2026 smoking-relapse window

This is exactly the kind of within-person pattern that matters more than population averages:
- higher resting HR
- higher walking HR
- lower HRV
- lower activity

That pattern fits the smoking literature well. Smoking heaviness has a causal link to higher resting HR (PMID: 26538566), and smoking cessation improves HRV (PMID: 23397454).

Practical interpretation: Apple Watch is already giving a personal physiologic penalty score for smoking, not just a future-risk lecture.

Alcohol/recovery signature: likely present, but it needs deliberate tagging

The imported data support the alcohol-recovery framework more than they prove it retrospectively.

The clearest candidate cluster is around the Feb 2026 re-exposure period:
- 2026-02-13: respiratory rate 29, SpO2 93.5%, HRV 24.2 ms, resting HR 66 bpm
- 2026-02-15: resting HR 66 bpm, HRV 31.7 ms, sleep 300 min after the big-party window noted in the cloud doc
- 2026-02-27 -> 2026-03-01: resting HR 75 -> 69 bpm, HRV 12.6 -> 17.6 ms, walking HR 94 -> 99 bpm, low activity
- 2026-03-21 -> 2026-03-27: repeated low-HRV / high-RHR / poor-sleep days with one SpO2 nadir at 91%

These are real physiologic disturbances, but the archive alone cannot say whether each was driven by alcohol, smoking, infection, travel disruption, poor sleep, or gut symptoms. The fix is simple: tag exposure days.

Best use going forward

Create explicit day tags for:
- alcohol: 0 / 1-2 / 3-5 / 6+ small beers
- smoking: none / light / heavy day
- gut status: stable / bloated / pain / loose stool / blood
- illness: yes/no

Then compare next-morning resting HR, HRV, respiratory rate, sleep, and same-day walking HR against a 28-day rolling baseline.

The 2026 alcohol paper is directly relevant here: acute alcohol exposure raised nocturnal resting HR, lowered HRV, shortened sleep, and reduced next-day activity in a dose-dependent fashion (PLOS Digital Health 2026, doi 10.1371/journal.pdig.0001284).

Iron question: Apple data do not yet prove an iron-depletion performance pattern

The original high-yield hypothesis was: falling ferritin should eventually show up as worse exercise efficiency or poorer recovery.

The current import does not yet prove that, mainly because the best physiologic signals are sparse during late Aug to Oct 2025. The archive does show:
- very high pre-bleed activity: ~11.7k steps/day from 2025-07-01 -> 2025-08-18
- major restriction after the bleed: ~3.9k steps/day from 2025-08-20 -> 2025-10-31
- recovery by Jan-Feb 2026: ~10.5k steps/day
- VO2 max estimate improved from a single Aug 2025 point of 25.4 to ~32.7 in Nov-Dec 2025 and ~33.5 in Mar-Apr 2026

That does not rule out iron-related exercise inefficiency. It only means the current summary layer is too crude. VO2 max from Apple Watch is directionally interesting but not accurate enough to carry the analysis alone; validation work found underestimation overall, overestimation in lower-fitness users, underestimation in higher-fitness users, and poor overall reliability (PMID: 39083800).

What would make the iron signal visible

The next-level analysis is not more blood tests first. It is a standardized workout-efficiency metric.

Use one repeatable benchmark:
- same route
- same duration or distance
- same time of day
- preferably similar fed/fasted state
- avoid smoking/alcohol confounding the prior evening

Track:
- average heart rate for the route
- pace or distance for the route
- next-morning resting HR
- next-morning HRV
- ferritin / CBC windows

Why this matters: non-anemic iron deficiency can impair exercise tolerance before dramatic anemia develops, and the effect is easier to see in performance and recovery than in one-off resting physiology alone (PMC10608302; JACC Case Reports 2026 nonanemic iron-deficiency case report).

Gut-inflammation use case: promising as a flare discriminator, not disease-specific proof

The imported data create a realistic way to separate inflammatory bad days from functional bad days.

Wearable studies in IBD found that HRV, HR, RHR, steps, and oxygenation shift during flare periods and can change up to 7 weeks before flares (PMID: 39826619). Diverticular disease is not IBD, so this is an extrapolation, not a validated disease-specific rule.

Still, it gives a useful decision frame:
- symptoms + rising resting HR + falling HRV + lower steps = more likely systemic inflammatory burden
- symptoms without physiologic disruption = more likely meal intolerance / post-inflammatory sensitivity / local gut irritation

Candidate future workflow:
1. Repeat calprotectin when symptoms are active.
2. Pull the prior 14-day wearable window.
3. Compare against rolling baseline.
4. Ask: was there a whole-body physiologic shift, or mainly symptoms?

That is likely to be more informative than CRP alone for this profile.

Cardiovascular use case: helpful for rhythm and recovery, not for plaque burden

For very high Lp(a), Apple Watch is useful in a narrow way:
- tracking resting HR / HRV trends
- catching symptom-time ECGs
- prompting BP monitoring discipline
- flagging unexplained reductions in exercise tolerance

It is not a structural risk monitor.

What the watch can meaningfully do

• Single-lead ECG during palpitations, chest discomfort, or unusual exertional episodes
• Longitudinal trend tracking of resting HR and HRV
• Recovery tracking after smoking/alcohol/stress

What it cannot do

• detect coronary plaque
• replace CAC/CCTA/echo
• clear a cardiac episode because the watch looked normal

Consumer wearables are strongest for AF screening, not broader arrhythmia rule-out; positive findings still need clinical confirmation with medical-grade evaluation (Cleveland Clinic Journal of Medicine 2024 review). For this profile, the one missing home metric with the highest ROI is still blood pressure, not more passive watch-derived novelty. AHA/ACC guidance and AHA patient guidance support home BP monitoring with an upper-arm automatic cuff.

Which Apple metrics deserve trust here

High-value

• Resting heart rate: good trend metric, especially for smoking/alcohol/recovery load
• HRV trend: useful within-person, not as an absolute score
• Walking heart rate average: useful early efficiency marker
• Sleep duration: useful covariate
• Respiratory rate: useful anomaly flag when it jumps above baseline
• Wrist temperature: useful overnight anomaly flag from supported watches

Medium-value

• VO2 max estimate: directional only
• SpO2: okay as a trend check when clearly abnormal, weak as a standalone metric; repeated breathing-disturbance / oxygen abnormalities belong in the sleep-apnea router, not in Apple-only diagnosis
• supported-model sleep-apnea notifications: useful prompt to seek objective HSAT/PSG, not proof of OSA

Low-value / overread risk

• Deep sleep / REM percentages
• single isolated HRV nights
• single isolated SpO2 dips

Sleep-device validation work supports this hierarchy: total sleep duration is decent, but stage estimates are much less reliable, and Apple Watch specifically tended to overestimate light sleep and underestimate deep sleep compared with polysomnography (PMID: 39460013).

Data already present but not fully exploited

The import includes:
- 94 GPX workout routes
- 16 ECG sidecar files
- 140 workouts total

A quick route check shows that some 2026 sessions are already usable as benchmarks:
- 2026-02-14 running route: ~3.36 km in 24.6 min (~7.32 min/km)
- 2026-03-10 running route: ~1.91 km in 14.2 min (~7.44 min/km)

The current summary artifact does not yet join route pace with heart-rate efficiency. That is the single best upgrade if the goal is to detect iron-related or smoking-related performance drift early.

Key Takeaways for This Profile

1. The strongest personal signal already visible is a smoking/autonomic signature: higher resting HR, higher walking HR, lower HRV, and lower activity in the relapse window.
2. The alcohol-recovery hypothesis is plausible in the data, but it needs explicit day tagging to separate alcohol from smoking, illness, and bad sleep.
3. The iron question is still open because the most interesting Aug-Oct 2025 period has poor wearable coverage; the answer will likely come from standardized route-efficiency tracking, not raw VO2 max.
4. Apple Health is better for flare discrimination and recovery tracking than for direct disease diagnosis.
5. For Lp(a), the most important missing home metric remains upper-arm blood pressure, not another blood panel or repeated Lp(a).
6. ECG recordings matter only when tied to symptoms. Silent background ECG collection is low-yield.
7. The current archive already contains enough route and ECG data to justify a second-pass analytic upgrade if needed.

Research Trace

• Research date: 2026-04-22
• Question type: clinical decision synthesis + wearable evidence review
• Internal sources used: cloud medical document, Apple Health summary JSON, and current KB owner sections for GI bleeding, CBC/thrombocytosis, Lp(a), and post-experiment testing
• External evidence anchors:
  • PMID: 39826619 - wearable physiology changes before and during IBD flares
  • PMID: 26538566 - smoking heaviness causally raises resting heart rate
  • PMID: 23397454 - smoking cessation improves HRV
  • PMID: 39083800 - Apple Watch VO2 max validation limits
  • PMID: 39460013 - sleep-stage accuracy limits for Apple Watch and peers
  • PMID: 40285070 / PMC12031371 - Apple Watch HRV validity best at rest, weaker in less controlled conditions
  • PMC10608302 - iron status and physical performance review
  • https://journals.plos.org/digitalhealth/article?id=10.1371/journal.pdig.0001284 - alcohol raises nocturnal RHR, lowers HRV, shortens sleep, lowers next-day activity
  • https://www.heart.org/en/health-topics/high-blood-pressure/understanding-blood-pressure-readings/monitoring-your-blood-pressure-at-home
  • https://www.acc.org/about-acc/press-releases/2025/08/13/20/03/new-high-blood-pressure-guideline-emphasizes-prevention-early-treatment-to-reduce-cvd-risk
  • https://support.apple.com/en-us/102674
• Unresolved gaps:
  • route-specific heart-rate efficiency is not yet derived into the summary artifact
  • symptom/exposure tagging is still missing, which limits causal interpretation of anomaly days

Monitor PSA Kinetics

urology · psa · prostate · cancer-screening · psa-velocity · mri

PSA Kinetics & Prostate Risk

Summary

The cloud doc records PSA 1.3 -> 1.5 -> 2.0 -> 2.85 ug/L across 2015-2026, with no urinary symptoms documented. This is close enough to work-up thresholds to repeat deliberately, but not a stand-alone cancer alarm.

AUA/SUO 2023 plus the 2026 amendment says repeat a newly elevated PSA before biomarkers, imaging, or biopsy, and do not use PSA velocity alone. EAU is more concrete for asymptomatic men: if PSA is 3-10 ng/mL and DRE is not suspicious, repeat after about 4 weeks; if it normalizes, resume interval follow-up.

Standardized repeat

Order at Biomed: PSA Total ($10, 1 day). If this is meant to resolve the branch rather than just trend it, add Free PSA / PSA Free ($15, 1 day) at the same draw so percent-free PSA can be interpreted.

Before the draw:

• Use the same lab/assay when practical.
• Avoid ejaculation, vigorous cycling, prostate manipulation, and testing during UTI/prostatitis/fever.
• Do not treat one borderline result as a biopsy decision; biologic and lab variation are large enough that repeat testing changes management.

Escalation table

Interpretation boundaries

• PSA velocity: useful as background trend, but not a stand-alone escalation rule. AUA/SUO explicitly says not to use velocity alone for biomarkers, imaging, or biopsy; Vickers/ERSPC repeat-biopsy data found weak added discrimination.
• Age-specific ranges: treat them as rough context, not a hard reassurance rule. At age 51, the issue is that PSA is now near action thresholds and has risen, not that it crosses a universal cancer cutoff.
• Percent-free PSA: helps risk stratification when total PSA is borderline, but it is context, not a yes/no cancer test.
• PSA density: requires prostate volume from ultrasound or MRI; >0.15 ng/mL/cc is a commonly used concern threshold, while EAU now discusses higher thresholds such as 0.20 when MRI is negative.
• DRE: not a sole screening tool, but useful alongside PSA when the branch remains active.

References

• AUA/SUO Early Detection Guideline Part I, 2023: PSA first, repeat newly elevated PSA, no PSA-velocity-only escalation, DRE/risk-calculator context. PMID: 37096582.
• AUA/SUO Part II and 2026 amendment: biomarkers/MRI/biopsy are for risk-stratified decisions focused on Grade Group 2+ disease. PMIDs: 37096575, 41744286.
• EAU Prostate Cancer Diagnostic Evaluation: repeat PSA under standardized conditions before further work-up in asymptomatic PSA 3-10 ng/mL with non-suspicious DRE. https://uroweb.org/guidelines/prostate-cancer/chapter/diagnostic-evaluation
• PSA velocity evidence: limited added value beyond PSA alone in ERSPC repeat-biopsy analysis. PMID: 20643434.
• Biomed Phnom Penh tariff checked 2026-05-03: PSA Total $10; Free PSA / PSA Free $15; both serum, 1-day turnaround.

Plan Phnom Penh Medical Access

phnom-penh · cambodia · hospitals · cardiology · imaging · dental · logistics · costs · pharmacies · devices

Phnom Penh Medical Access Guide

Healthcare Infrastructure · Costs · Availability · Phnom Penh, Cambodia

This is the canonical local-logistics page. Specialty articles should link here for access/cost/call-script details rather than duplicating hospital notes that can go stale.

Key Hospitals in Phnom Penh

Royal Phnom Penh Hospital (RPPH)

• Operator: BDMS Group (Bangkok Dusit Medical Services) — Thailand's largest private hospital chain
• Cardiology: Cardiology Center with Thai cardiac specialists, Cardiac Catheterization Lab, Cardiac Care Unit. Performs percutaneous coronary intervention (PCI).
• Historical personal paper trail: 2024-01-22 RPPH outpatient workup delivered right lower-extremity arterial Doppler, hip/pelvis radiology, cardiology/orthopedic review, and medication dispensing. Private archive ID rpph-2024-01-22-cardiology-orthopedic-papers.
• Imaging: Official 128-slice CT scanner page plus an official “CT scan package for coronary screening.” The 2026 Heart Packages poster also lists CTA Coronary in Platinum. Treat RPPH as a real local coronary-CT route, but call before booking to confirm CAC vs contrast CCTA vs both, ECG gating, report fields, radiation dose, and package/standalone price (023 991 000 / 012 991 000).
• Echocardiogram: Public 2026 Heart Packages poster lists echocardiogram in Gold and Platinum packages; this remains the priority local baseline route for Lp(a)-related aortic-valve screening.
• Sleep apnea: Public RPPH sleep article describes sleep specialist consultation, in-lab polysomnography, and home sleep apnea testing (HSAT); use as Phnom Penh-first route if OSA triggers appear.
• Endoscopy: Dedicated GI specialists offering gastroscopy and colonoscopy packages
• Liver screening: Public RPPH Healthy Liver Screening Package poster lists FibroScan plus upper-abdominal ultrasound (liver/pancreas/gallbladder) and physician examination. The poster offer date expired on 2025-12-31; use this only as a service lead until phone confirmation of current availability, kPa/CAP reporting, and price.
• Standards: JCI accredited. "Hospital of the Year – Cambodia" award.
• Language: English-speaking staff

Khema International Hospital

• Locations: Toul Kork (#18, St. 528, 099 667 066) and BKK1 (28, Street 294, +855 89 911 911)
• Services: Cardiology, 24/7 emergency, ICU, advanced diagnostics. French-trained doctors (Dr. Sok, graduated in France).
• CT scanner: Unconfirmed if they have cardiac-rated CT (128+ slice with ECG gating). General CT likely available but cardiac angiography requires specific capabilities. Call to ask.
• Reputation: Listed in Australian Embassy medical providers. Solid facility but smaller than RPPH.

Bumrungrad Hospital Bangkok — Phnom Penh Office

• Location: 4th floor, Building 19&20, EXCHANGE SQUARE, St. 106, Phnom Penh
• Accreditation: JCI Accredited
• Doctors: 1,200+ at main Bangkok hospital
• Open: 9am-9pm
• Role: Consultation/booking office for Bumrungrad Bangkok — can arrange referral, testing, and treatment in Bangkok
• Relevance: Direct pathway to Bangkok for Repatha, advanced cardiac workup, or Lp(a) specialist referral

Rung Reung Heart Clinic

• Specialized cardiac screening clinic in Chrouy Changvar, Phnom Penh
• Cardiac screening: $50-$150
• Good for basic cardiac assessment (ECG, echo) — may not have advanced imaging

KHMER-THAI HOSPITAL / Calmette Hospital

• Calmette: Public teaching hospital with cardiology department (Dr. Youdaline Theng, cardiology specialist)
• Lower cost but potentially more language barrier and longer wait times

Service Availability & Cost Estimates

Public-source snapshot (checked 2026-05-08)

Cardiac Imaging

Source note (2026-05-08): RPPH official pages checked: 128-slice CT scanner, CT coronary-screening package, cardiology center, acute MI diagnostic page, Heart Packages posters, sleep-test article, and Healthy Liver poster. Biomed tariff was scraped directly from the live table; prices are subject to change.

GI Procedures

Liver / MASLD / Fibrosis Screening

Liver call-script: “I need liver fibrosis/steatosis risk stratification, not just routine LFTs. Can I book FibroScan/VCTE? Will the report include liver stiffness in kPa, IQR/median reliability, probe used, CAP or steatosis score, and physician interpretation? Can upper-abdominal ultrasound be added or separated from the package?”

Sleep Apnea Testing

Dental / Periodontal Care

Dental call-script: “I want a periodontal screening because blood markers are persistently inflammatory. Please record pocket depths, bleeding on probing, gum recession/attachment loss, tooth mobility, furcation if relevant, and whether X-rays show bone loss or abscess. If periodontitis is present, can you do scaling/root planing and give a maintenance interval?”

Source note (2026-05-04): Roomchang homepage/staff pages (https://roomchang.com/, https://roomchang.com/m/meet-our-staff/), Malis periodontitis page (https://malis-dental.com/en/dental-care/periodontitis), and Pagna periodontal-treatment page (https://pagnadental.com/periodontal-treatment/). Treat public pages as service leads; exact clinician/treatment plan still needs booking confirmation.

SIBO / Hydrogen-Methane Breath Testing / Bile-Acid Diarrhea

• Local availability remains unconfirmed after 2026-05-08 public-source refresh. No official Phnom Penh source was found that clearly advertises hydrogen/methane SIBO breath testing, SeHCAT, serum C4-for-BAD, FGF19, or fecal bile-acid testing.
• Biomed tariff scrape on 2026-05-08 found no FIT, SeHCAT, BAD-specific C4, FGF19, fecal bile-acid, hydrogen/methane, or SIBO rows; do not treat Biomed as a BAD/SIBO-testing route unless the counter confirms a send-out.
• RPPH has a GI Center and lists gastroscopy/colonoscopy, but not breath or BAD testing on its public GI page.
• Khmer Medical lists Phnom Penh gastroenterologists who can review bloating/SUDD/SIBO/BAD-like symptoms, but public listings do not confirm test access.
• Call-script: “Do you offer hydrogen and methane breath testing for SIBO/IMO, using glucose or lactulose substrate, and do you report methane as well as hydrogen? If repeated stool logs show chronic watery urgency, can you test bile-acid diarrhea with SeHCAT, fasting serum C4, or 48-hour fecal bile acids, or would treatment be only empirical?”

Home Monitoring Devices / Pharmacy Delivery

• Preferred ordering path: Grab Mart search across UCare and other major pharmacy/home-care merchants, then verify the exact model before buying. UCare itself is an officially registered Cambodian pharmacy network and offers delivery through multiple apps; GrabMart search results also index UCare and home-care equipment merchants in Phnom Penh.
• BP monitor rule: buy a validated upper-arm cuff with the correct cuff circumference. Confirm model number and cuff range in cm from the listing or pharmacy chat before ordering.
• Good search terms: Omron blood pressure, Microlife blood pressure, A&D blood pressure, upper arm blood pressure monitor, plus the exact model (for example HEM-7361T).
• Validation check: look up the exact model in STRIDE BP or ValidateBP. Brand alone is not enough; validation is model-specific.
• Current sourcing note (2026-05-03): Omron Cambodia/Asia pages list upper-arm connected models including HEM-7361T, HEM-7156T, HEM-7143T1, HEM-7142T1, and HEM-7141T1. STRIDE BP confirms HEM-7361T; HEM-7143T1/M2 Intelli IT variants appear in STRIDE BP home-device lists. HEM-7141T1/7142T1 were found on Omron pages but not confirmed in STRIDE/PubMed during this pass.
• Avoid as first choice: generic CK-A156 devices indexed on GrabMart/home-care pages unless the seller can provide validation evidence. Search found device listings and FDA-clearance-style material, but not STRIDE BP / ValidateBP confirmation.

Repatha (Evolocumab) — PCSK9 Inhibitor

Legacy access notes below require direct refresh before use; PCSK9 escalation logic is owned by Prevention Status + CVD Burden and Lp(a) Therapy Watchlist.

• Not found available in Cambodia directly — no online pharmacy or hospital listing for Repatha in Phnom Penh
• Bangkok source: Repatha is available in Thailand at BDMS hospitals (Bangkok Hospital, Bumrungrad, etc.)
• Legacy Thailand cost estimate: verify current hospital/pharmacy price before relying on it. Prior rough note: Repatha 140mg autoinjector estimated THB 3,000-6,000/month ($85-170/month).
• Access strategy: Use Bumrungrad Phnom Penh office (Exchange Square, St.106) to arrange supply or visit Bangkok for prescription
• Can also arrange Repatha supply through RPPH (BDMS network) — they may be able to source from Thailand

IV Iron (Ferinject/Ferric Carboxymaltose)

• Available at major private hospitals with infusion capability
• RPPH has the infrastructure for IV infusion
• Cost: estimated $50-150 per infusion session (varies by dose)
• If oral iron (bisglycinate) fails after 8 weeks or a clinician recommends IV repletion, IV iron is likely a hospital/hematology route; verify directly before relying on RPPH availability, formulation, dose, and price.

Lp(a) Specialist Referral

For comprehensive Lp(a) management and advanced testing:

Bangkok (closest high-end option):
- Siriraj Hospital (Mahidol University) — Division of Cardiology, has published Lp(a) research on Thai populations
- Heart Center, Bangkok Hospital Pattaya — offers ApoB, Lp(a), sdLDL testing and management
- H.U.M. Clinic Bangkok — specialized in ApoB, Lp(a), cardiovascular risk assessment

Phnom Penh (local baseline):
- RPPH cardiology team (Thai specialists) can handle basic workup and order Lp(a) testing

Key Takeaways

1. RPPH (Royal Phnom Penh Hospital, BDMS group) is the strongest local workup hub: 128-slice CT, cardiology/cath lab, heart packages with echo and CTA Coronary, GI endoscopy packages, sleep testing/consultation, and liver package poster with FibroScan + upper-abdominal ultrasound.
2. CCTA/CAC: public evidence is now stronger than “maybe” because RPPH lists CTA Coronary in Platinum and a CT coronary-screening page exists, but the booking question is still exact content: CAC, contrast CCTA, or both; ECG gating; stenosis/plaque fields; radiation dose; and price.
3. Echocardiogram: RPPH Heart Packages list echo in Gold/Platinum; use this as the Phnom Penh-first baseline aortic-valve route.
4. Biomed stool-blood logistics: FOB/occult blood is listed at $7.50 and Stool Direct Exam at $2; FIT/quantitative FIT is not public, so ask counter about send-out but do not treat it as available.
5. Biomed CBC/iron logistics appear cheap and practical as of the 2026-05-08 public tariff scrape; clinician-reviewed peripheral smear and JAK2/CALR/MPL are not public Biomed rows and belong to hospital/hematology/send-out confirmation if triggered.
6. SIBO and bile-acid testing remain unconfirmed locally; ask GI/RPPH only if logs make the branch actionable.
7. Liver/FibroScan: RPPH poster lists a service lead and legacy package prices ($189/$239/$299), but the poster offer date expired on 2025-12-31; use this only as a service lead until phone confirmation of current availability, kPa/CAP reporting, and price.
8. Dental/periodontal source check remains locally feasible; Roomchang is the highest-capacity first lead, with Malis/Pagna as practical alternatives. Ask for periodontal charting rather than just cosmetic cleaning.
9. Home BP devices: order through Grab Mart/UCare-style pharmacy channels when possible, but verify exact model/cuff size/validation first; generic unvalidated monitors are not good enough for medical decision-making.